

METROPOLITAN HEALTH NETWORKS INC

Form S-1

May 28, 2004

Table of Contents

As filed with the Securities and Exchange Commission on May 28, 2004.

Registration No. _____

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20459**

FORM S-1

**REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933**

METROPOLITAN HEALTH NETWORKS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida
(State or Other Jurisdiction of
Incorporation or Organization)

8011
(Primary Standard Industrial
Classification number)

65-0635748
(I.R.S. Employer
Identification No.)

**250 Australian Avenue South, Suite 400
West Palm Beach, FL 33401
(561) 805-8500**
(Address and Telephone Number of Principal Executive Offices)

**Michael M. Earley, President and Chief Executive Officer
250 Australian Avenue South, Suite 400
West Palm Beach, FL 33401**
(Name, Address and Telephone Number of Agent For Service)

Copies of all communications to:

**Joel D. Mayersohn, Esq.
Adorno & Yoss, P.A.
350 East Las Olas Boulevard, Suite 1700
Fort Lauderdale, FL 33301
Telephone: (954) 763-1200
Facsimile No. (954) 766-7800**

Approximate Date of Proposed Sale to the Public: As soon as practicable after the effective date of this Registration Statement.

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. []

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. []

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. []

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. []

If delivery of this prospectus is expected to be made pursuant to Rule 434, please check the following box. []

Table of Contents**CALCULATION OF REGISTRATION FEE**

Title of Each Class of Securities	Amount to be	Proposed Maximum Offering Price	Proposed Maximum Aggregate	Amount of Registration Fee
To be Registered	Registered	Per Security	Offering Price	
Common Stock, par value \$0.001 per share (1)	5,715,697	\$ 0.84	\$4,801,185	\$ 608.31

(1) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457. Based upon the average of the closing bid and asked prices for the common stock on May 21, 2004.

We hereby amend this Registration Statement on such date or dates as may be necessary to delay its effective date until we file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting under Section 8(a), may determine.

Table of Contents

Registration No. _____

PROSPECTUS

Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This prospectus shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

SUBJECT TO COMPLETION

**METROPOLITAN HEALTH
NETWORKS, INC.**

5,715,697 Shares of Common Stock

This prospectus covers the 5,715,697 shares of common stock of Metropolitan Health Networks, Inc. being offered for resale by certain selling security holders.

Our common stock is traded on the OTCBB under the trading symbol **MDPA** . On May 21, 2004, the closing price for our common stock was \$0.84.

This investment involves a high degree of risk. You should purchase shares only if you can afford a complete loss of your investment. See Risk Factors beginning on page 4.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

You should rely only on the information contained in this document or that we have referred you to. We have not authorized anyone to provide you with information that is different. This prospectus does not constitute an offer of any securities other than those to which it relates or an offer to sell, or a solicitation of any offer to buy, to any person in any jurisdiction where such an offer or solicitation would be unlawful. Neither the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create an implication that the information set forth herein is correct as of any time subsequent to the date hereof.

_____, 2004

TABLE OF CONTENTS

<u>Prospectus Summary</u>	2
<u>Risk Factors</u>	4
<u>Forward-Looking Statements</u>	6
<u>Capitalization</u>	7
<u>Price Range of Common Stock and Dividend Policy</u>	7
<u>Use of Proceeds</u>	7
<u>Management's Discussion and Analysis or Plan of Operation</u>	8
<u>Inflation and Price Changes</u>	13
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	13
<u>Business</u>	14
<u>Description of Property</u>	16
<u>Legal Proceedings</u>	17
<u>Management</u>	18
<u>Executive Compensation</u>	20
<u>Principal Shareholders</u>	22
<u>Certain Relationships and Related Transactions</u>	23
<u>Description of Securities</u>	24
<u>Selling Security Holders</u>	25
<u>Plan of Distribution</u>	27
<u>Shares Eligible for Future Sale</u>	28
<u>Indemnification of Officers and Directors</u>	28
<u>Legal Matters</u>	28
<u>Experts</u>	28
<u>Additional Information</u>	28
<u>Financial Statements</u>	F-1
<u>Opinion of Adorno & Yoss, P.A.</u>	
<u>Form of Subscription Agreement</u>	
<u>Amendment No 1 to Note w/ Global Funding Group</u>	
<u>Subscription Agreement</u>	
<u>6% Convertible Debenture</u>	
<u>Consent of Kaufman, Rossin & Company</u>	

All dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

Table of Contents

PROSPECTUS SUMMARY

This summary contains what we believe is the most important information about us and the offering. You should read the entire document for a complete understanding of our business and the transactions in which we are involved. The purchase of the securities offered by this prospectus involves a high degree of risk. Risk factors include the lack of revenues and history of loss, and the need for additional capital. See the Risk Factors section of this prospectus for additional risk factors.

References throughout this prospectus to Metcare , we , us and our are to Metropolitan Health Networks, Inc. and its subsidiaries.

The Company

Business Description

Metropolitan Health Networks, Inc. provides healthcare benefits to over 25,000 Medicare Advantage members (formerly Medicare+Choice) in Central and South Florida under full-risk contracts with Humana, Inc., the second largest participant in this Medicare program. Metcare entered into this business in 1999, operating a Provider Service Network (PSN), also known as a Managed Service Organization (MSO).

The PSN includes thirty-three (33) primary care physician practices. Metcare owns six of these practices; the balance are independently owned and operated under capitation contracts with the Company. In addition to the primary care practices, the PSN contracts with specialists, ancillary service providers, and hospitals. The Company also owns and operates an oncology practice, which is part of the network.

Under its risk agreements, Metropolitan receives credit for a significant percentage of the monthly Medicare premiums received by Humana from the Centers for Medicare and Medicaid Services (CMS) and is obligated to provide all of the covered healthcare benefits for the member lives. To the extent the costs of providing such benefits is less than the related premiums received, Metropolitan profits. Conversely, if the costs exceed related premiums, the Company loses money. The Company re-insures against catastrophic losses and certain diseases annually on a per member basis. The annual stop-loss limits are \$100,000 and \$40,000 per member in the Daytona and South Florida markets, respectively.

The Medicare Advantage business accounts for the majority of the Company's revenues. In addition, Metcare cares for commercial insurance members and fee for service patients in its wholly owned practices.

Our executive offices are located at 250 Australian Avenue South, Suite 400, West Palm Beach, Florida 33401, and our telephone number is (561) 805-8500.

The Offering

Selling Shareholders

This prospectus covers up to 5,715,697 shares of our common stock, which may be sold by the selling stockholders identified in this prospectus.

Summary financial data

The following summary of our financial information has been derived from our audited financial statements.

Result of Operations

	Year Ended December 31, 2003	Year Ended December 31, 2002	Year Ended Dec. 31, 2001	Year Ended Dec. 31, 2000	6 Months Ended December 31, 1999	Year Ended June 30, 1999
Revenues	\$ 143,874,488	\$ 140,063,566	\$ 128,186,307	\$ 119,047,520	\$ 10,020,795	\$ 18,501,497
Expenses	<u>139,472,735</u>	<u>157,144,453</u>	<u>128,555,548</u>	<u>114,724,369</u>	<u>\$ 16,235,281</u>	<u>\$ 28,821,313</u>
Net Income (Loss)	4,401,753	(17,080,887)	(369,241)	4,323,151	\$ (6,214,486)	(10,319,816)
Net earnings (loss) Per Share						
(basic)	0.13	(0.56)	(0.02)	0.25	(0.58)	(1.44)
(diluted)	<u>0.10</u>	<u>(0.56)</u>	<u>(0.02)</u>	<u>0.21</u>	<u>(0.58)</u>	<u>(1.44)</u>

Table of Contents**Balance Sheet Data**

	As of Dec. 31, 2003	As Of Dec. 31, 2002	As of Dec. 31, 2001	As of Dec. 31, 2000	As of Dec. 31, 1999
Working Capital (Deficit)	\$(2,370,044)	\$ (7,827,412)	\$ 3,125,927	\$ (1,133,782)	\$(12,543,611)
Total Assets	\$ 9,223,729	\$10,158,911	\$17,379,262	\$11,159,834	\$ 7,033,580
Total Liabilities	\$ 9,726,390	\$17,027,204	\$10,683,441	\$10,924,619	\$ 16,546,186
Shareholder s Equity	\$ (502,661)	\$ (6,868,293)	\$ 6,695,821	\$ 235,215	\$ (9,512,606)

Result of Operations Quarterly 2003 & 2004

	Unaudited 3 Months Ended March 31, 2004	Unaudited 3 Months Ended December 31, 2003	Unaudited 3 Months Ended September 30, 2003	Unaudited 3 Months Ended June 30, 2003	Unaudited 3 Months Ended March 31, 2003
Revenues	\$38,543,196	\$35,452,435	\$35,680,129	\$35,865,376	\$36,876,548
Expenses	\$37,098,387	\$33,887,045	\$34,507,157	\$34,917,682	\$36,160,851
Net Income (loss)	\$ 1,444,809	\$ 1,565,390	\$ 1,172,972	\$ 947,694	\$ 715,697
Net Earnings (loss)					
Per Share (basic)	0.03	0.04	0.03	0.03	0.02
(diluted)	0.03	0.04	0.03	0.02	0.02

Result of Operations Quarterly 2002

	Unaudited 3 Months Ended December 31, 2002	Unaudited 3 Months Ended September 30, 2002	Unaudited 3 Months Ended June 30, 2002	Unaudited 3 Months Ended March 31, 2002
Revenues	\$ 34,838,083	\$34,613,150	\$36,191,511	\$34,420,822
Expenses	\$ 48,287,764	\$36,602,375	\$38,283,079	\$33,968,959
Net Income (loss)	(13,449,681)	\$ (1,989,225)	(2,091,568)	451,863
Net Earnings (loss)				
Per Share (basic)	(0.43)	(0.06)	(0.07)	0.02

(diluted)

(0.43)

(0.06)

(0.07)

0.01

Table of Contents

RISK FACTORS

Prospective investors should carefully consider, along with other matters referred to herein, the following risk factors.

Failure to manage our growth effectively could harm our business and results of operation.

We have experienced growth in our business during the last three years. Continued growth may impair our ability to provide our services efficiently and to manage our employees adequately. Our strategy is to focus on growth within geographic parameters, identifying regions throughout Florida. Future results of operations could be materially adversely affected if we are unable to manage our growth effectively.

Our quarterly results will likely fluctuate, which could cause the value of our common stock to decline.

We are subject to quarterly variations in our medical expenses due to fluctuations in patient utilization. We have significant fixed operating costs and, as a result, are highly dependent on patient utilization to sustain profitability. Our results of operations for any quarter are not necessarily indicative of results of operations for any future period or full year. We experience increased patient population and greater use of medical services in the winter months. As a result, our results of operations may fluctuate significantly from period to period. In addition, there recently has been significant volatility in the market price of securities of health care companies that in many cases we believe has been unrelated to the operating performance of these companies. We believe that certain factors, such as legislative and regulatory developments, quarterly fluctuations in our actual or anticipated results of operations, lower revenues or earnings than those anticipated by securities analysts, and general economic and financial market conditions, could cause the price of our common stock to fluctuate substantially.

The loss of certain agreements and the capitated nature of our revenues could materially affect our operations.

The majority of our revenues come from agreements with one managed care organization that provides for the receipt of capitated fees. The principal organization that we contract with is Humana. We have one-year renewable agreements with Humana to provide healthcare services to members in certain healthcare networks established or managed by Humana. For the twelve months ended December 31, 2003, approximately 99% of our revenue was obtained from these agreements. The Humana agreements may be terminated in the event we participate in activities Humana reasonably believes may adversely affect the health or welfare of any member or other material breach, or upon 180-day notice of non-renewal by either party. Failure to maintain these agreements, or successfully develop additional sources of revenue could adversely affect our financial condition. A continuing decline in enrollees in Medicare Advantage could also have a material adverse effect on our profitability.

Under Humana agreements we, through our affiliated providers, generally are responsible for the provision of all covered hospital benefits, as well as outpatient benefits, regardless of whether the affiliated providers directly provide the healthcare services associated with the covered benefits. To the extent that enrollees require more care than is anticipated, aggregate capitation rates may be insufficient to cover the costs associated with the treatment of enrollees. If revenue is insufficient to cover costs, our operating results could be adversely affected. As a result, our success will depend in large part on the effective management of health care costs. Pricing pressures may have a material adverse effect on our operating results. Changes in health care practices, inflation, new technologies, and other factors affecting the delivery and cost of health care are beyond our control and may adversely affect our operating results.

Reimbursement for Our Managed Care Operations will be affected by the Medicare Risk Adjustment

The Balanced Budget Act of 1997 directed the Health Care Financing Administration (now CMS) to replace the existing system of risk adjustment, which previously relied solely on demographic factors, with one that took enrollees' health status into account (the Medicare Risk Adjustment or MRA). The demographic-only portion of the payment was adjusted for age, gender, Medicaid eligibility, institutional status and working aged status. The revised MRA portion of the payment, however, includes these same categories but adds health status as a new criteria. Such health status is measured by the previous medical costs for inpatient hospital stays incurred by the individual. These are then used to determine each individual's expected future medical risk and, therefore, how much the health plan in which they are enrolled should be paid. To ensure that health plans had time to adjust to the new payment method, CMS built a five-year transition period into the MRA methodology it adopted. The initial data used to facilitate the transition to MRA was based solely upon inpatient hospital encounter data. For 2000 and 2001, under the Balanced Budget Refinement Act of 1999 (BBRA) the transition to risk adjustment was based upon a blend percentage consisting of 10% risk adjustment payment and 90% on the adjustment for demographic factors. For 2002, the blend percentage was adjusted to 20% risk adjustment payment and 80% on the adjustment for demographic factors. The law requires that the ambulatory data be incorporated beginning January 1, 2004, at which time the blend percentage will consist of 30% risk adjustment payment and 70% on the adjustment for demographic factors. In 2005, the blend percentage will consist of 50% risk adjustment payment and 50% on the

Table of Contents

adjustment for demographic factors. In 2006, the blend percentage will consist of 75% risk adjustment payment and 25% on the adjustment for demographic factors. In 2007, the blend percentage will consist of 100% risk adjustment payment and 0% on the adjustment for demographic factors. Through Fiscal 2003, our payments from the HMOs have substantially been based on the demographic model. However, in Fiscal 2004, we anticipate that the payments we receive from the HMOs will begin reflecting the MRA methodology. At this time, it cannot be determined if this impact will be favorable or unfavorable in future years.

The development of management information systems may involve significant time and expense.

Our management information systems are important components of the business and are becoming a more significant factor in our ability to remain competitive. We already possess a physician billing and collection system. We are participating in the development of an integrated management information system. The development and implementation of such systems involve the risk of unanticipated delay and expense, which could have an adverse impact on our operations.

The high cost of insurance could adversely affect our financial operation.

As a result of the national malpractice award trends and the significant loss of professional insurance underwriting capacity, the cost of our medical malpractice insurance has increased while the coverage afforded under the policies available has decreased. Additionally, as a result of the events of September 11, 2001, as well as recent high profile director and officer related litigation, the cost of our director and officer insurance policy has increased. We anticipate that the cost for both our medical malpractice insurance as well as our director and officer insurance will increase in 2004. We also maintain stop-loss insurance for which the premium is based on a cost per member. We may experience future increases in stop-loss insurance, which could have a material adverse effect on our business, financial condition and results of operations.

Our industry is already very competitive; increased competition could adversely affect our revenues.

The health care industry is highly competitive and subject to continual changes in the method in which services are provided and the manner in which health care providers are selected and compensated. Companies in other health care industry segments, some of which have financial and other resources greater than we do, may become competitors in providing similar services. We may not be able to continue to compete effectively in this industry. Additional competitors may enter our markets and this increased competition may have an adverse effect on our revenues.

We are dependent upon our key management personnel for our future success.

Our success depends to a significant extent on the continued contributions of our key management. We have no insurance policies for our executive officers. The loss of these key personnel could have a material adverse effect on our financial condition, results of operations and plans for future development. While we have employment contracts with certain key members of management, we compete with other companies for executive talent and there can be no assurance that highly qualified executives would be readily available.

The health care industry is highly regulated and our failure to comply with laws or regulations, or a determination that in the past we have failed to comply with laws or regulations, could have an adverse effect on our financial condition and results of operations.

The health care services that we and our affiliated professionals provide are subject to extensive federal, state and local laws and regulations governing various matters such as the licensing and certification of our facilities and personnel, the conduct of our operations, our billing and coding policies and practices, our policies and practices with

regard to patient privacy and confidentiality, and prohibitions on payments for the referral of business and self-referrals. If we fail to comply with these laws, or a determination is made that in the past we have failed to comply with these laws, our financial condition and results of operations could be adversely affected. Changes to health care laws or regulations may restrict our existing operations, limit the expansion of our business or impose additional compliance requirements. These changes, if effected, could have the effect of reducing our opportunities or continued growth and imposing additional compliance costs on us that may not be recoverable through price increases.

Federal anti-kickback laws and regulations prohibit certain offers, payments or receipts of remuneration in return for referring Medicaid or other government-sponsored health care program patients or patient care opportunities or purchasing, leasing, ordering, arranging for or recommending any service or item for which payment may be made by a government-sponsored health care program. In addition, federal physician self-referral legislation, known as the Stark law, prohibits Medicare or Medicaid payments for certain services furnished by a physician who has a financial relationship with various physician-owned or physician-interested entities. These laws are broadly worded and, in the case of the anti-kickback law, have been broadly interpreted by federal courts, and potentially subject many business arrangements to government investigation and prosecution, which can be costly and time consuming. Violations of these laws are punishable by monetary fines, civil and criminal penalties, exclusion from participation in government-sponsored health care programs and forfeiture of amounts collected in violation of such laws, which could have an adverse effect on our business and results of operations. Florida also has anti-kickback and self-referral laws, imposing substantial penalties for violations.

Table of Contents

Limitations of or reduction in reimbursement amounts or rates by government-sponsored healthcare programs could adversely affect our financial condition and results of operations.

As of December 31, 2003, approximately 99% of our revenues were derived from reimbursements by various government-sponsored health care programs. These government programs, as well as private insurers, have taken and may continue to take steps to control the cost, use and delivery of health care services. The following events could result in an adverse effect on our financial condition and results of operations:

reductions in or limitations of reimbursement amounts or rates under programs,

reductions in funding of programs,

elimination of coverage for certain individuals or treatments under programs, which may be implemented as a result of increasing budgetary and cost containment pressures on the health care industry, or

new federal or state legislation reducing funding and reimbursements.

We have anti-takeover provisions which may make it difficult to replace or remove our current management.

Our Articles of Incorporation authorize the issuance of up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined from time to time by the Board of Directors. Our Board of Directors may, without shareholder approval, issue preferred stock with dividends, liquidation, conversion, voting or other rights, which could adversely affect the voting power, or other rights of the holders of our common stock. The ability of our board to issue preferred stock may prevent or frustrate shareholder attempts to replace or remove current management.

Due to the substantial number of our shares that will be eligible for sale in the near future, the market price of our common stock could fall as a result of sales of a large number of shares of common stock in the market, or the price could remain lower because of the perception that such sales may occur.

These factors could also make it more difficult for us to raise funds through future offerings of our common stock. As of April 30, 2004, there were 45,711,008 shares of our common stock outstanding, all of which are freely tradable without restriction with the exception that approximately 6,500,000 shares, which are owned by certain of our officers, directors, affiliates and third parties, and may be sold publicly at any time subject to the volume and other restrictions under Rule 144 of the Securities Act of 1933.

In addition, as of April 30, 2004, approximately 9,700,000 shares of our common stock were reserved for issuance upon the exercise of warrants and options which have been previously granted.

Our common stock has experienced in the past, and is expected to experience in the future, significant price and volume volatility, which substantially increase the risk of loss to persons owning common stock.

Because of the limited trading market for our common stock, and because of the possible price volatility, you may not be able to sell your shares of common stock when you desire to do so. The inability to sell your shares in a rapidly declining market may substantially increase your risk of loss because of such illiquidity and because the price for our common stock may suffer greater declines because of its price volatility.

FORWARD LOOKING STATEMENTS AND ASSOCIATED RISKS

Except for historical information contained herein, the matters discussed in this report are forward-looking statements made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on the Company's expectation and are subject to a number of risks and uncertainties, including but not limited to economic, competitive and other factors affecting the Company's operations, ability of the Company to obtain competent medical personnel, the cost of services provided versus payment received for capitated and full risk managed care contracts, negative effects of prospective healthcare reforms, the Company's ability to obtain medical malpractice coverage and the cost associated with malpractice, access to borrowed or equity capital on favorable terms, the fluctuation of the Company's common stock price, and other factors discussed elsewhere in this report and in other documents filed by the Company with the Securities and Exchange Commission from time to time. Many of these factors are beyond the Company's control. Actual results could differ materially from the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this report will, in fact, occur.

Table of Contents**CAPITALIZATION**

The following table sets forth our capitalization as of March 31, 2004. The table should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this prospectus.

	March 31, 2004
Current maturities of long-term debt	\$ 485,966
Long-term debt	\$ 802,436
Stockholders' Equity:	
Common Stock, \$.001 par value, 80,000,000 shares authorized, 45,692,748 shares issued and outstanding	\$ 45,693
Preferred Stock, \$.001 par value, 10,000,000 shares Authorized, 5,000 shares issued or outstanding	\$ 500,000
Additional paid-in capital	\$ 35,419,206
Accumulated deficit	\$(30,793,524)
Other	\$ (163,489)
Total stockholders' equity	\$ 5,007,886

PRICE RANGE OF COMMON STOCK AND DIVIDEND POLICY

Our shares of common stock are traded on the OTCBB under the symbol MDP.AOB. The following tables set forth the high and low closing bid prices for the common stock as reported by OTCBB:

Common Stock

Period	High	Low
January 1, 2001-March 31, 2001	1.844	0.875
April 1, 2001-June 30, 2001	3.340	1.930
July 1, 2001-September 30, 2001	2.900	1.750
October 1, 2001-December 31, 2001	2.080	1.030
January 1, 2002-March 31, 2002	1.400	0.670
April 1, 2002-June 30, 2002	0.830	0.450
July 1, 2002-September 30, 2002	0.470	0.180
October 1, 2002-December 31, 2002	0.470	0.170
January 1, 2003-March 31, 2003	0.270	0.140
April 1, 2003-June 30, 2003	0.200	0.070
July 1, 2003-September 30, 2003	0.340	0.130
October 1, 2003-December 31, 2003	0.790	0.260
January 1, 2004-March 31, 2004	1.100	0.670

As of April 30, 2004, there were approximately 1,200 holders of our common stock. Holders of our common stock are entitled to cash dividends if, and when, declared by the board of directors. We do not intend to pay any dividends in the foreseeable future and investors should not rely on an investment in us if they require dividend income. We intend to retain earnings, if any, to finance the development and expansion of our business. Future dividend policy will be subject to the discretion of our board of directors and will be based upon future earnings, if any, our financial condition, capital requirements, general business conditions and other factors. There can be no assurance that cash

dividends of any kind will ever be paid.

USE OF PROCEEDS

We will not receive any proceeds from the sale of the shares of common stock by the selling shareholders.

Table of Contents

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS
AND RESULTS OF OPERATIONS**

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company's management to make a variety of estimates and assumptions. These estimates and assumptions affect, among other things, the reported amounts of assets and liabilities, the disclosure of contingent liabilities and the reported amounts of revenues and expenses. Actual results can differ from the amounts previously estimated, which were based on the information available at the time the estimates were made.

The critical accounting policies described below are those that the Company believes are important to the portrayal of the Company's financial condition and results, and which require management to make difficult, subjective and/or complex judgments. Critical accounting policies cover accounting matters that are inherently uncertain because the future resolution of such matters is unknown. The Company believes that critical accounting policies include accounts receivable and revenue recognition, use of estimates and goodwill.

Accounts Receivable and Revenue Recognition

The Company is a party to certain managed care contracts and provides medical care to its patients through owned and non-owned medical practices. In connection with its Provider Service Network (PSN) operations, the Company is exposed to losses to the extent of its share of deficits. Accordingly, revenues under these contracts are reported as PSN revenue, and the cost of provider services under these contracts are reported as an operating expense.

The Company recognizes non-Humana revenues, net of contractual allowances, as medical services are provided. These services are typically billed to patients, Medicare, Medicaid, health maintenance organizations, insurance companies and other third parties. The Company provides an allowance for uncollectible amounts and for contractual adjustments relating to the difference between standard charges and agreed upon rates paid by certain third party payers.

Use of Estimates-PSN

In HMO-PSN arrangements, accounts receivable estimates often change as a result of one or more future confirming events. With regard to revenues, expenses and resulting accounts receivable arising from agreements with Humana, the Company estimates amounts it believes will ultimately be realizable through the use of judgments and assumptions. Contractual terms with an HMO are sometimes complex and at times subject to different interpretation by the Company and Humana. As a result, certain revenue, expense and accounts receivable estimates may change from amounts previously recorded in the financial statements and may require subsequent adjustments. To assist in estimating and collecting amounts due from Humana, the Company has contracted with several outside consultants that have worked closely with Humana or other HMOs for extended periods of time. These consultants provide numerous services including, but not limited to, revenue, expense and accounts receivable analysis, and monthly claims and contestation analysis. However, it is possible that actual results may differ from the estimates.

Direct medical expenses include costs incurred directly by the Company and costs paid by the HMO on the Company's behalf. These costs also include estimates of claims incurred but not reported (IBNR), estimates of retroactive adjustments to be applied by Humana and adjustments for charges which the Company believes it is not liable (contestations). The IBNR estimates are made by Humana utilizing actuarial methods and are continually evaluated and adjusted by management of the Company, based upon its specific claims experience and input from outside consultants. The Company bases its estimates of retroactive adjustments on agreements with the HMO to

modify previous charges. Some of these adjustments have been quantified while others involve situations where Humana has agreed the charges were processed at incorrect rates, but the amount of the correction has not yet been quantified. Contestations involve charges where the Company, with the assistance of its consultants, contest certain expenses charged by the HMO. The estimate of direct medical expense includes an estimated recovery of 20% of outstanding contestations with Humana. It is possible that estimates of such recoveries could change and the effect of the change could be material.

Accounts receivable from Humana represents the combined effect of the Company's interpretation of the contract with the HMO and its payment patterns. Collection times on these accounts typically exceed normal collection periods reflecting the need to reconcile the different interpretations and the HMO's cash management practices.

Goodwill

The Company has made several acquisitions in the past that included a significant amount of goodwill. Under accounting principles generally accepted in the United States of America in effect through December 31, 2001, these assets were amortized over

Table of Contents

their useful lives and tested periodically to determine if they were recoverable from operating earnings on a discounted basis over their useful lives.

Effective January 1, 2002, goodwill is accounted for under SFAS No. 142, Goodwill and Other Intangible Assets. The new rules eliminate amortization of goodwill but subject these assets to impairment tests. Management is required to make assumptions and estimates, such as the discount factor, in determining fair value. Such estimated fair values might produce significantly different results if other reasonable assumptions and estimates were to be used.

Quarter ended March 31, 2004

Results of Operations

The Company generated revenues of \$38.5 million for the quarter ended March 31, 2004 compared to \$36.9 million in the prior year quarter, an increase of \$1.7 million (4.5%). Net income for the 2004 quarter was \$1.4 million, compared to net income of \$716,000 for the quarter ended March 31, 2003, an improvement of \$729,000 or 101.9%. The 2003 quarter included approximately \$249,000 in losses related to its discontinued pharmacy operations, compared to \$46,000 in the current year quarter. On a basic per share basis, net income was \$0.03 for the quarter ended March 31, 2004, compared to per share net income of \$0.02 in the prior year quarter.

The Company operated two business segments in 2003, managed care and direct medical services (PSN) and pharmacy. The Company disposed of its pharmacy division in November 2003 and, accordingly, the operations of the pharmacy division are shown as losses from discontinued operations. The remaining PSN segment, prior to allocation of corporate overhead, reported an increase in its income as a percentage of revenue, from 6.3% in the first quarter of 2003 to 6.9% in the current year period.

Revenues

Revenues for the quarter ended March 31, 2004 increased nearly \$1.7 million (4.5%) over the prior year, from \$36.9 million to \$38.5 million. PSN revenues from Humana increased 4.8%, from \$36.5 million to \$38.2 million. Approximately \$3.4 million in incremental revenues were generated by governmental funding increases ranging from an estimated 9.8% in Daytona and 15% in Palm Beach County. These increases were partially offset by declines in the number of patients in our Daytona and South Florida networks, resulting in approximately \$942,000 in reduced funding. In addition, effective August 1, 2003 the Company cancelled its risk arrangement with one of its South Florida centers due to noncompliance with the Company's policies and procedures, resulting in a funding decrease of \$710,000.

Total Medicare Advantage lives declined approximately 1,600 members from March 31, 2003 to a membership of approximately 25,200 at March 31, 2004. Approximately 500 of the decline resulted from the terminated Broward County center, with the other 1,100 attributable to attrition. However, as a result of the increased funding provided by the Medicare Modernization Act, or MMA, which was signed into law in December 2003, the Company believes this trend will reverse and enrollment in its network will increase over the balance of 2004. The funding increases are intended to both offset medical cost inflation and to allow enhanced plan benefit design to encourage increased participation in Medicare Advantage plans.

Non-Humana revenue for Metcare's wholly owned physician practices in the first quarter of 2004 declined \$97,000 over the same period in 2003, to a total of \$308,000. The Company operated six physician practices and an oncology center in both quarters.

Expenses

Operating expenses for the quarter ended March 31, 2004 increased \$1.4 million (3.9%) over the prior year quarter, from \$35.5 million to \$36.9 million. Operating expenses other than direct medical costs and medical supplies, which correlate to revenue, decreased 2.9% over the prior year quarter.

Direct medical costs, the largest component of expense, represents costs associated with providing services of the PSN operation including direct medical payments to physician providers, hospitals and ancillaries on a capitated or fee for service basis. Direct medical costs for the first quarter of 2004 were \$33.2 million compared to \$31.9 million for 2003, an increase of 4.4%. The increase reflects the results of a flu season that was the severest in four years, resulting in increased hospital admissions and lengths of stay, combined with overall increases in health care costs over the past year.

Salaries and benefits for the quarter was virtually the same as the prior year's total of \$1.9 million. An increase of approximately \$102,000 resulted from the hire of an oncologist in late 2004, whereas in 2003 a consultant was utilized. Additionally, savings of approximately \$168,000 were realized through the closure of the Company's hospitalist program in early 2003. Salary increases combined with increased benefit costs accounted for the balance of the incremental expense.

Medical supplies were \$511,000 for the 2004 quarter, compared to \$429,000 in 2003. Medical supply costs are incurred in all the

Table of Contents

Company's medical offices, but most prominently in the Company's Daytona oncology offices, accounting for 91.2% of the 2004 expense. The 2004 quarter included \$31,000 of incremental expense relating to the purchase of flu vaccine for its Daytona network.

Depreciation and amortization for the quarter ended March 31, 2004 totaled \$123,000, a 26.8% decrease over the prior year total of \$167,000, as many of the Company's fixed assets are fully depreciated.

Rents and leases for the quarter ended March 31, 2004 increased \$44,000 over the prior year quarter. When the Company negotiated the lease for its new corporate office effective January 2003, it received certain rent concessions in the first quarter of 2003.

Consulting expense for the quarter decreased approximately \$265,000 (65.1%), from \$407,000 in 2003 to \$142,000 in 2004. Of the reduction, \$103,000 resulted from the hiring of an oncologist, whereas in the prior year a consultant was utilized. In addition, approximately \$114,000 in savings was realized through a reduction in marketing and administrative consultants and the closure of the Company's hospitalist program in early 2003.

General and administrative expenses for the 2004 quarter amounted to \$702,000, an increase of \$133,000 over the prior year quarter. Legal and accounting expenses increased \$168,000 primarily related to the Company's restructuring activities. Insurance costs increased \$87,000 reflective of increased insurance costs for policies renewed mid-2003. Savings in other areas partially offset these increases.

Other income and expenses for the quarter included a decrease in interest expense of \$232,000 from the prior year due to the decreased average amount of debt and IRS obligations carried by the Company in the 2004 quarter as compared to the prior year.

Losses from the discontinued pharmacy operations for the quarter, was \$46,000 in 2004 as compared to \$249,000 in 2003. The pharmacy operations were sold in November 2003.

Liquidity and Capital Resources

During the quarter, the Company reduced its current liabilities from \$7.8 million to \$2.5 million and its total liabilities from \$9.7 million to \$3.3 million. Most significantly, the Company settled its longstanding payroll tax obligation. The Company's net worth totaled \$5.0 million at March 31, 2004 compared to a deficit of \$503,000 at December 31, 2003. Additionally, working capital improved from a deficit of \$2.4 million at year-end 2003 to a surplus of \$2.1 million at March 31, 2004.

Also during the quarter, the Company issued 290,980 shares of common stock for the exercise of stock options, board compensation and loan fees. In addition, the Company issued 1,869,070 shares of common stock for the conversion of \$1,015,000 of long-term debt and 5,005,000 shares in a private placement related to its IRS settlement, as discussed below. The shares were sold at \$0.60 per share and these issuances were completed pursuant to exception from registration under the Securities Act of 1933.

In addition, the Company repaid \$709,000 of long-term debt that was due in the quarter and finalized an extension, for payment over twenty-four months, of approximately \$1.2 million in additional debt due May 2004.

In 2000, the Company negotiated an installment plan with the Internal Revenue Service (IRS) related to unpaid payroll tax liabilities, including accrued interest and penalties. Under the plan the Company was required to make monthly installments of \$100,000 on the amount in arrears. The agreement expired and the full amount was deemed due upon demand.

In February 2004, the Company was successful in negotiating a settlement with the IRS on its outstanding payroll tax liabilities for an amount totaling approximately \$3.3 to \$3.4 million. To date, \$3.2 million of this settlement has been paid with the balance to be paid once the IRS has determined the final settlement amount.

Comparison of Fiscal 2003 and Fiscal 2002

Introduction

Revenues for the year ended December 31, 2003 totaled \$143.9 million compared to \$140.1 million in the prior year. Net income was \$4.4 million for the year ended December 31, 2003 compared to a net loss of \$17.1 million in 2002. On a per share basis, the Company earned \$0.13 for the year ended December 31, 2003, compared to a loss of \$0.56 in the prior year. Income from continuing operations amounted to \$5.9 million in 2003, compared to a net loss of \$13.9 million in 2002. Results for 2002 included significant adjustments to direct medical costs of approximately \$6.6 million, imputed interest expense of \$1.2 million and \$520,000 in write-downs of accounts receivable from medical practices closed in prior years.

Included in the 2003 and 2002 years were \$1.5 million and \$3.2 million, respectively, of losses related to the discontinued operations. The Company operated two business segments in 2003, managed care and direct medical services (PSN) and pharmacy. It

Table of Contents

operated a third segment in 2002, the clinical laboratory business, which was disposed of in July 2002. The pharmacy business was established in 2001 and sold in November 2003.

As discussed in the audited financial statements, the PSN segment reported a gain of \$11.5 million before allocated overhead of \$3.7 million for 2003, compared to a loss of \$5.0 million in 2002 and a gain of \$6.1 million in 2001. Segment revenues for the same time periods were \$143.9 million, \$140 million and \$128.2 million, respectively. Expenses, which include direct medical costs and supplies, physician salaries and other costs relating to the operations of medical practices, were \$132.2 million, \$147.2 million, and \$122.7 million for the years ended December 31, 2002, 2001 and 2000, respectively.

Revenues

Revenues for the year ended December 31, 2003 increased \$3.8 million or 2.7% over the prior year, from \$140.1 million to \$143.9 million. PSN revenues from Humana increased 2.8%, from \$138.5 million to \$142.3 million. Approximately \$12.1 million in incremental revenues were generated by funding increases resulting from the renegotiation of the Company's contract with Humana in the Daytona market, combined with governmental funding increases of approximately 1.8%. These increases were partially offset by a decline in the number of patients in our Daytona network, resulting in approximately \$6.7 million in reduced funding. In connection with the renegotiation of its Daytona HMO contract, the Company was no longer at risk for the HMO's commercial membership effective January 1, 2003, resulting in lost revenue of approximately \$3.1 million for the year, but increased profitability as this line of business had been unprofitable.

The Company's South Florida centers reported a net increase in PSN revenues from Humana of \$1.6 million over the prior year period, with \$1.4 million in increases from a new center in Broward County, which the Company assumed management of in October 2002, and \$1.9 million due to increased membership at its Boca Raton medical office. Effective August 1, 2003 the Company cancelled its risk arrangement with the Broward County center due to noncompliance with the Company's policies and procedures. These revenue increases were partially offset by \$1.7 million in decreases due to net decreased membership in the Company's other South Florida medical centers.

Total Medicare Advantage lives declined approximately 1,700 members from year-end 2002 to a membership of approximately 25,500 at December 31, 2003. Approximately 500 of these belong to the terminated Broward County center, with the other 1,200 attributable to attrition.

Non-Humana revenue for Metcare's wholly owned physician practices in 2003 remained the same as the prior year, \$1.6 million. The Company operated six physician practices and an oncology center in each of the years.

Expenses

Operating expenses for the year ended December 31, 2003 decreased \$14.3 million (9.5%) over the prior year, from \$151.0 million to \$136.7 million. Operating expenses other than direct medical costs and medical supplies, which correlate to revenue, decreased 12.5% over the prior year due in part to several cost cutting measures undertaken by the Company in late 2002 and 2003.

Direct medical costs, the largest component of expense, represents costs associated with providing services of the PSN operation including direct medical payments to physician providers, hospitals and ancillaries on a capitated or fee for service basis. Direct medical costs for 2003 were \$121.0 million compared to \$133.6 million for 2002, a decrease of \$12.6 million, or 9.4%, despite a \$3.8 million increase in HMO revenues. A savings of \$3.5 million in expenses was realized in 2003 due to no longer being at risk for commercial membership in conjunction with the Company's renegotiated Daytona HMO contract. Included in 2002 were significant adjustments to direct medical costs of

approximately \$6.6 million relating to prior years. The Company was able to obtain its own stop-loss insurance in the Daytona market in 2003, accounting for additional savings estimated at approximately \$2.4 million.

Salaries and benefits for 2003 increased 1.9% over 2002, from \$7.7 million to \$7.8 million. Increases were comprised of approximately \$400,000 in management and staff bonuses, increases of \$378,000 in the Company's growing Boca Raton medical and Daytona oncology offices and \$67,000 related to the Company's Daytona operations. Offsetting the increases were approximately \$139,000 in savings resulting from the closure of two unprofitable medical practices in 2002 and \$676,000 related to the termination of the Company's hospitalist program in the first quarter.

Medical supplies were \$2.1 million for 2003, compared to \$1.9 million in 2002, as the 2002 expense only represented ten months of operations for the Company's Daytona oncology offices. Medical supply costs are incurred in all the Company's medical offices, but most prominently in the Company's Daytona oncology offices, accounting for 94.0% of the 2003 expense.

Depreciation and amortization for the year ended December 31, 2003 totaled \$655,000, a 30.8% decrease over the prior year total of \$946,000. The prior year included \$429,000 in amortization and write-offs of financing costs, compared to \$164,000 in the current year.

Table of Contents

Rent and leases for the year ended December 31, 2003 totaled \$1.0 million, a \$162,000 increase over 2002. Approximately \$100,000 of the increase resulted from increased rent at the Company's new corporate offices, with another \$119,000 arising from the expansion of the aforementioned Boca Raton and oncology medical offices. These increases were offset in part by \$56,000 in savings resulting from the closure of the medical practices previously mentioned.

Consulting expense for the year decreased approximately \$1.3 million, or 49.3%, from \$2.7 million in 2002 to \$1.4 million in 2003. These savings resulted in part from \$273,000 in reductions of consulting services connected with the Company's pharmacy and HMO development efforts. Further savings were achieved through the discontinued use of medical consultants in the Company's hospitalist program in the first quarter of 2003 amounting to \$973,000, a \$314,000 reduction in marketing consultants and \$81,000 in savings due to a closed medical practice in July 2002. These reductions were partially offset by \$303,000 in increases related to the development of the Company's oncology practice.

General and administrative expenses for the year decreased \$492,000, or 16.1%, from the \$3.0 million reported in the year ended December 31, 2002. The result of cost cutting measures undertaken by the Company in the second half of 2002 and 2003, decreases were recognized in a wide number of expense categories, most significantly in legal and accounting. These reductions were partly offset by an increase in insurance costs amounting to \$158,000.

Other income and expenses for 2003 included a decrease in interest expense of \$1.1 million from the prior year, as 2002 included \$1.2 million of imputed interest due to beneficial conversion features on convertible notes. The difference of \$100,000 is due to the increased average amount of debt carried by the Company in 2003 as compared to the prior year.

Loss from discontinued operations for the year, which includes the Company's pharmacy division in 2003 and both the pharmacy and clinical laboratory in 2002, was \$1.7 million in 2003 compared to \$2.4 million in 2002. The 2003 year also included a \$290,000 gain on the disposal of the pharmacy division, while 2002 reported a \$834,000 loss on the disposal of the clinical laboratory.

Comparison of Fiscal 2002 and 2001

Introduction

The Company generated revenues of \$140.1 million for the year ended December 31, 2002 compared to \$128.2 million in the prior year, and incurred a net loss of \$17.1 million for the year ended December 31, 2002 compared to a net loss of \$369,000 for the year ended December 31, 2001. On a per share basis, losses were \$0.56 and \$0.02 for the years ended December 31, 2002 and December 31, 2001, respectively. Included in 2002 are significant adjustments to direct medical costs of approximately \$6.6 million, imputed interest expense of \$1.2 million, \$520,000 in write-downs of accounts receivable remaining on medical practices closed in prior years and \$3.2 million in losses related to the discontinued operations of the Company's clinical laboratory and pharmacy businesses.

Generally accepted accounting principles (GAAP) require the Company to make certain revenue and cost estimates with regards to its contracts with the HMO. Programs with the HMO are complex and at times subject to various interpretations. These revenue and cost estimates may be settled for amounts different than previously estimated or the Company's estimate could change by amounts that could be material to the financial statements. The nature of the relationship with the HMO is, and has been such, that certain estimates made by the Company are based upon verbal agreements with, or representations from the HMO regarding retroactive adjustments to amounts previously credited or charged to Metcare's fund balance. These estimates are particularly likely to change as policy, and/or personnel, at Humana changes. In connection with a change in Humana's management during 2002, deterioration in the relationship

with Humana in the fourth quarter of 2002, and other factors, during 2002 Metcare recorded additional medical costs of approximately \$6.6 million related to amounts that were included in accounts receivable at December 31, 2001. Conversely in 2001, upon favorable resolution of unsettled medical costs, Metcare recorded a reduction to medical costs of approximately \$1.9 million.

In the fourth quarter of 2002 the Company incurred significant increases in Part A (hospital) and related costs due to the loss of a hospital contract by Humana in the Company's Daytona network. In response to the increased costs, management approached Humana in the fourth quarter of 2002 seeking to renegotiate its contract. The Company successfully completed an amendment to offset the cost increases, allowing the Daytona market to be financially viable. The amendment was effective January 1, 2003 and provides for increased funding in addition to other financial concessions. In return, the Company made certain concessions, a portion of which related to the charge to direct medical expenses discussed above.

In conjunction with a convertible debenture financing completed in May 2002, the Company incurred charges to interest of approximately \$1.2 million. These charges were necessary as the holder may convert the debt at any time into company stock at a price lower than it was at the issuance of the debt.

Table of Contents

As discussed in the audited financial statements, the Company operated in three segments for fiscal years 2002 and 2001; managed care and direct medical services (PSN), pharmacy and clinical laboratory. The largest of these, the PSN division, reported a loss before allocated overhead of \$5.0 million for 2002, compared to profits of \$6.1 million in 2001 and \$4.5 million in 2000. Revenues for the same time periods were \$140.1 million, \$128.2 million and \$119.0 million, respectively. Expenses, which include direct medical costs and supplies, physician salaries and other costs relating to the operations of medical practices, were \$147.0 million, \$122.7 million and \$114.5 million for the years ended December 31, 2002, 2001 and 2000, respectively.

During 2001 the Company formed its pharmacy division. For the years ended December 31, 2002 and 2001, the pharmacy division reported losses, before allocation of corporate overhead, of \$1.8 million and \$744,000, respectively. For those same periods, revenues were \$12.9 million compared to \$2.8 million, while expenses, which include the costs of pharmaceuticals and other related expenses, were \$15.8 million and \$3.8 million for 2002 and 2001, respectively. The pharmacy was disposed of in November 2003 and, accordingly, the operations of this division are included in the loss from operations of discontinued business segments.

In the third quarter of 2002, the Company decided to dispose of its third segment, its clinical laboratory. Accordingly, in the year ended December 31, 2002, the Company recognized \$1.4 million in losses on discontinued operations, compared to losses of \$559,000 in 2001 and \$95,000 in 2000.

Revenues

Revenues for the year ended December 31, 2002 increased \$11.9 million, or 9.3%, over the prior year, from \$128.2 million to \$140.1 million. PSN revenues, the core of the Company's business, increased 9.1%, from \$126.9 million to \$138.5 million, due primarily to funding increases from revisions to the Balanced Budget Act of approximately \$7.5 million and approximately \$4.0 million resulting from increased membership. In addition, revenues for 2002 included \$635,000 of fee-for-service billings relating to the Company's newly formed Daytona oncology practice. Offsetting these increases were decreases in revenue from the closure of certain medical practices in 2002 and the second half of 2001 of \$388,000.

Expenses

Operating expenses for the year ended December 31, 2002 increased approximately 20.0%. Direct medical costs, the largest component of expense, represent certain costs associated with providing services of the PSN operation including direct medical payments to physician providers, hospitals and ancillaries on a capitated or fee-for-service basis. Direct medical costs for 2002 were \$133.6 million compared to \$114.6 million for 2001. During the year the Company implemented several utilization initiatives, including its hospitalist, partners in quality (PIQ), and oncology programs, in an effort to improve patient care and reduce its medical costs. In the fourth quarter, the Company incurred significant increases in Part A (hospital) and related costs due to the loss of a hospital contract by Humana in the Company's Daytona network. In response to the increased costs, management renegotiated the Company's contract with the Humana. The Company successfully completed an amendment, which offset the cost increases, allowing the Daytona market to be financially viable. The amendment was effective January 1, 2003 and provided for increased funding in addition to other financial concessions.

Salaries and benefits for the year increased 26.7% over 2001, from \$6.1 million to \$7.7 million. PSN expansion in South Florida accounted for approximately \$415,000 in increases while expansion of the services the Company provides in its Daytona market in an effort to improve patient care and control medical costs accounted for another \$1.2 million of increases. Salary increases, increases in medical insurance premiums and a bolstering of staffing throughout the Company accounted for the balance of the increase, which was partially offset by \$269,000 in savings achieved by the closure of two unprofitable medical practices.

Medical supplies were \$1.9 million for 2002, compared to \$63,000 in 2001, due to the implementation of the Company's oncology practice in early 2002. Medical supply costs are incurred in all the Company's medical offices, but most prominently in the Company's two Daytona oncology offices, accounting for 96.8% of the 2002 supplies expense.

Depreciation and amortization for the year ended December 31, 2002 totaled \$946,000, an increase of \$101,000 over the prior year. The increase is due primarily to depreciation on fixed assets acquired in 2002 as well as the amortization recorded on certain financing costs incurred during the year.

Rent and leases for the year ended December 31, 2002 totaled \$854,000, a \$97,000 increase over 2001. The aforementioned new operations accounted for a majority of the increase, with the balance resulting from annual increases in rent in our corporate and medical offices. This was offset in part by \$84,000 in savings resulting for the closure of the medical practices previously mentioned.

Consulting expense increased approximately \$1.6 million, from \$1.1 million in 2001 to nearly \$2.7 million in 2002. Of the increase, \$1.3 million was incurred in the Company's Hospitalist, Oncology and Utilization/Quality Assurance/Management programs, which

Table of Contents

are designed to lower direct medical costs while improving patient care. In addition, approximately \$386,000 of incremental expense was incurred in connection with investment banking and advisory services.

General and administrative expenses increased from \$2.3 million in 2001 to \$3.0 million in 2002, an increase of \$770,000. Costs associated with the Company's oncology and hospitalist programs and other PSN expansion accounted for \$411,000 in incremental expense. Increases also were incurred in accounting and legal fees (\$245,000) and insurance (\$158,000). The prior year also included approximately \$313,000 in accounts payable write-offs and settlements relating to discontinued operations. These increases were partially offset by the savings of \$115,000 resulting from the closure of a medical practice in the second half of 2001 and a \$196,000 decrease in billing and collection fees from 2001 to 2002 resulting from the renegotiation and eventual cancellation of the Company's contract with an outside billing company in the second half of 2001.

Other income and expenses for the year ended December 31, 2002 included write downs of accounts receivable from medical practices closed in prior years of \$520,000 and \$3.2 million in losses on discontinued operations relating to the Company's clinical laboratory and pharmacy divisions. Interest expense increased \$1.8 million for the year, due in large part to the previously mentioned charge of \$1.2 million incurred in conjunction with a Convertible Debenture financing completed in May 2002. The balance of the increase is due to the increased amount of debt carried by the Company at December 31, 2002 as compared to the prior year.

Liquidity and Capital Resources

For the year ended December 31, 2003 the Company reported a profit of \$4.4 million and over \$2.1 million in positive cash flows from operations, significant improvements over the prior year results. These results combined with proceeds from the sale of the Company's pharmacy business and convertible debt conversions have enabled the reduction in liabilities by more than \$7.3 million during the year, with additional reductions occurring in the first quarter of 2004 as detailed below. Prior to 2003, however, the Company had historically sustained negative cash flows from operations, in part as a result of the Company's diversification efforts, including the pharmacy and clinical laboratory operations. In 2003 the Company determined to refocus on its core managed care business. Although the Company expects its cash flow from operations to continue to be positive, there can be no assurance that this will occur. In the absence of continuing positive cash flows from operations or obtaining additional debt or equity financing, the Company may have difficulty meeting current and long-term obligations.

In the fourth quarter of 2002 the Company incurred significant increases in Part A (hospital) and related costs due to the loss of a hospital contract by Humana in the Company's Daytona network. In response to the increased costs, management successfully renegotiated its Daytona contract, allowing it to be financially viable. The amendment was effective January 1, 2003 and provided for increased funding in addition to other financial concessions. The 2003 results reflect the effects of the contract revision.

During the first quarter of 2003, the Company borrowed an additional \$500,000 from an existing lender on a short-term note bringing the total balance to \$1 million, which note was due August 21, 2003. The note was renegotiated during the year extending the due date and was subsequently paid down to \$620,000 at December 31, 2003. The balance of this note was repaid in the first quarter of 2004.

The Company borrowed \$1.3 million from Humana during the first half of 2003, which amount was repaid over the course of the year.

The Company sold the operations of its pharmacy division in November 2003 for a cash price of \$3.1 million plus the assumption of approximately \$1.1 in liabilities. The pharmacy incurred losses of \$1.5 million and \$1.8 million in 2003 and 2002, respectively. The Company believes that this sale will result in both improved profitability and cash

flows.

During 2003, approximately \$1.1 million of long-term debt was paid through the issuance of 2.3 million shares, as provided for in the terms of the Convertible Notes with the investors. In January 2004, the remaining balance of \$715,000 on a Convertible Note was paid in full through the issuance of 1.3 million shares of common stock. In March 2004, two Notes due August 2004 totaling \$300,000 were repaid through the issuance of approximately 611,000 shares of common stock. Additionally, the Company's remaining significant note payable for \$1.2 million due May 2004 was extended, with payments due over a twenty-four month period beginning June 2004.

In February 2004 the Company successfully negotiated a settlement with the Internal Revenue Service (IRS) on outstanding payroll tax liabilities for an amount totaling approximately \$3.3 to \$3.4 million. \$3.2 million of this settlement has been paid with the balance to be paid once the IRS has determined the final settlement amount.

In conjunction with its IRS settlement, in February 2004 the Company raised approximately \$3 million through the issuance of approximately 5.0 million shares of common stock under a private placement offering. The proceeds went toward the settlement of the IRS obligations.

Table of Contents

Membership in Medicare Advantage programs (previously Medicare+Choice) has declined as a percentage of Medicare eligible lives over the last several years, principally the result of decreased funding which has negatively impacted plan benefits. Although the Company has seen growth in its membership through its expansion of its relationship with Humana, Metcare has experienced gradual attrition in membership commensurate with the industry. Net membership decreases from attrition were approximately 1,200 or 4.4% in 2003. The Company expects this trend to reverse with the passage of the Medicare Modernization Act in late 2003. Among a number of sweeping changes to Medicare, the legislation is intended to substantially increase participation in Medicare Advantage through increased funding commitments. Beginning with an average increase of 10.6% in 2004, this stimulus allows plans to improve benefits and attract new enrollees. With total 2004 premium increases of approximately 9.8% in Daytona and 17.8% in South Florida, and the resulting benefit enhancements, the Company expects its Medicare membership to grow. As well, Metcare expects that opportunities to expand into other Florida markets will develop as Humana and other Medicare HMO s grow their respective businesses.

The underlying economics of the Medicare Modernization Act may also provide sufficient incentive for companies such as Metcare to directly enter the Medicare Advantage business. The Company is currently evaluating its opportunities in the Florida, particularly in underserved markets, and may file for its own Medicare HMO license in 2004. The decision to enter this business would necessarily be based on a number of factors including analysis of the opportunity, consideration of alternative strategies and availability of necessary capital.

INFLATION AND CHANGING PRICES

Dependency on Reimbursement by Third-Parties

The Medicare and Medicaid programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings and funding restrictions, any of which could have the effect of limiting or reducing reimbursement levels. A substantial portion of our managed care revenues are based upon Medicare reimbursable rates. Any changes that limit or reduce Medicare reimbursement levels could have a material adverse effect on our business. Further, significant changes have or may be made in the Medicare program, which could have a material adverse effect on our business, results of operations, prospects, financial results, financial condition or cash flows. In addition, the Congress of the United States may enact unfavorable legislation, which could adversely affect operations by, among other things, decreasing Medicare reimbursement rates.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk generally represents the risk of loss that may result from the potential change in value of a financial instrument as a result of fluctuations in interest rates and market prices. We do not currently have any trading derivatives nor do we expect to have any in the future. We have established policies and internal processes related to the management of market risks which we use in the normal course of our business operations.

Interest Rate Risk

The fair market value of long-term debt is subject to interest rate risk. While changes in market interest rates may affect the fair value of our fixed-rate long-term debt, we believe a change in interest rates would not have a material impact on our financial condition, future results of operations or cash flows.

Intangible Asset Risk

We have a substantial amount of intangible assets. Although at December 31, 2003 we believe our intangible assets are recoverable, changes in the economy, the business in which we operate and our own relative performance could change the assumptions used to evaluate intangible asset recoverability. We continue to monitor those assumptions and their consequent effect on the estimated recoverability of our intangible assets.

BUSINESS

Description of Business

Introduction

Metropolitan Health Networks, Inc. provides healthcare benefits to over 25,000 Medicare Advantage members (formerly Medicare+Choice) in Central and South Florida under full-risk contracts with Humana, Inc., the second largest participant in this Medicare program. Metcare entered into this business in 1999, operating a Provider Service Network (PSN), also known as a Managed Service Organization (MSO).

Table of Contents

The PSN includes thirty-three (33) primary care physician practices. Metcare owns six of these practices; the balance are independently owned and operated under capitation contracts with the Company. In addition to the primary care practices, the PSN contracts with specialists, ancillary service providers, and hospitals. The Company also owns and operates an oncology practice, which is part of the network.

Under its risk agreements, Metropolitan receives credit for a significant percentage of the monthly Medicare premiums received by Humana from the Centers for Medicare and Medicaid Services (CMS) and is obligated to provide all of the covered healthcare benefits for the member lives. To the extent the costs of providing such benefits is less than the related premiums received, Metropolitan profits. Conversely, if the costs exceed related premiums, the Company loses money. The Company re-insures against catastrophic losses and certain diseases annually on a per member basis. The annual stop-loss limits are \$100,000 and \$40,000 per member in the Daytona and South Florida markets, respectively.

The Medicare Advantage business accounts for the majority of the Company's revenues. In addition, Metcare cares for commercial insurance members and fee for service patients in its wholly owned practices.

Background

The Company was incorporated in the State of Florida in January 1996, and began operations as a physician practice group. During the late 1990's Metcare acquired a number of physician practices and ancillary service providers. In late 1999, the group practice strategy was abandoned in connection with a change in the senior management team.

The first managed care risk contract was secured with Humana in 1999. In 2000, an additional contract was subsequently secured to manage all of Humana's Medicare Advantage lives in the Daytona, Florida area (Flagler and Volusia Counties). The Daytona contract currently accounts for over 19,000 lives or 77% of the Company's total Medicare Advantage lives. The balance of the Company's Humana lives reside in South Florida (Palm Beach, Broward and Miami-Dade Counties).

Metropolitan renegotiated its most significant contract with Humana, in Daytona, effective January 1, 2003. This renegotiation increased the percentage of Medicare premium received by Metcare and resolved a number of contractual disputes.

Metcare acquired a diagnostic laboratory business, renamed Metlabs, Inc., in 2000. This operation was subsequently shut down in 2002. The Company formed Metcare Rx, a pharmacy business, in 2001. This business was sold in November 2003.

Metropolitan's Board of Directors replaced the Company's President and CEO in March 2003, and subsequently adopted a strategy to focus its resources and energies on its core managed care business. In December 2003, the Medicare Prescription Drug Improvement and Modernization Act of 2003 (the Medicare Modernization Act or MMA) was signed into law, which, among other changes, is significantly increasing funding for the Medicare Advantage program beginning in 2004. Included in the MMA was the establishment of a significant federal marketing budget to promote the Medicare Advantage program. The stated goal is to triple enrollment in this program over the next several years.

Industry

A report issued in early 2004 by CMS estimated that national healthcare spending in the United States was nearly \$1.7 trillion, or \$5,800 for every American, in 2003. The CMS report projected that healthcare spending, which today

accounts for more than 15% of the national economy, would grow to \$3.4 trillion by 2013, more than 18% of projected Gross Domestic Product. The principal drivers for this growth include continued cost-increasing medical innovation, rising price inflation, continued strong demand for prescription drugs and the aging baby-boomer demographics. The CMS projections did not give effect to the December 2003 Medicare Modernization Act, other than to note that new legislation is not anticipated to have a large impact on overall spending but is expected to cause sizable shifts in payment sources.

Medicare currently provides healthcare benefits to 41 million elderly and disabled Americans, and was established in 1965. This number is expected to more than double by 2030. The newly renamed Medicare Advantage program (formerly Medicare+Choice) represents private health plans participation in the Medicare program. Under Medicare Advantage plans, private insurers provide care under contracts with Medicare. These plans represent an alternative to traditional fee-for-service Medicare and by definition must provide enhanced benefits in exceeding traditional Medicare by at least 30%. Some of these enhancements include prescription drugs, eye exams, hearing aids and routine physical exams. Out-of-pocket cost for the beneficiary may be lower and choice of physicians is typically restricted to the plan's network.

This participation of private health plans under risk contracts began in the 1980's and grew to a peak membership in 2000 when Medicare HMOs covered 6.3 million lives. Today, private plans account for slightly more than 10% of Medicare members, down from a peak penetration of 18%. The Balanced Budget Act of 1997 resulted in significant funding decreases causing the

Table of Contents

number of participating plans to drop from 346 in 1998 to 151 in 2003. The exodus of managed care companies from Medicare left many of its beneficiaries without a private plan option.

The Medicare Modernization Act, or MMA, was signed into law in December 2003, and provides sweeping changes to the Medicare program. At an estimated cost of over \$400 billion for the next ten years, the new law provides for a Medicare prescription drug offering beginning in 2006, establishes new tax-advantaged Health Savings Account regulation and makes significant changes to the old Medicare+Choice (now Medicare Advantage) program. The changes to the Medicare Advantage program were a response to the decreased managed care participation in Medicare and the resulting lack of choice for Medicare beneficiaries. The MMA made favorable changes to the premium rate calculation methodology and generally provides for program rates that will better reflect the increased cost of medical services provided to Medicare beneficiaries. The new rates for 2004 were announced in January 2004 reflecting an average increase of 10.6%, which will be reflected in funding beginning in March 2004. The funding increases are intended to both offset medical cost inflation and to allow enhanced plan benefit design to encourage increased participation in Medicare Advantage plans.

Markets

Metcare currently provides healthcare services to nearly 6,000 Medicare Advantage beneficiaries in South Florida (Palm Beach, Broward and Miami-Dade Counties) and to over 19,000 members in the Daytona area (Flagler and Volusia Counties). Behind only California, which has nearly 4 million Medicare eligibles, Florida has the second largest Medicare population in the U.S. with almost 3 million lives. However, California's Medicare Advantage penetration is approximately 30% while Florida's is only 20%. The most significant counties in terms of Medicare Advantage membership currently include Palm Beach, Broward, Miami-Dade and Volusia. Florida's Medicare population is expected to grow to 4 million by 2015.

Business Model

Metcare provides turnkey healthcare services to Medicare Advantage beneficiaries who participate in the Medicare Advantage program through Humana, Inc. Our current agreements with Humana have one-year terms and renew automatically for additional one-year terms unless terminated for cause or on 180-days prior notice. Humana is paid a certain premium per member, per month, for its Medicare Advantage members by Medicare under its contract with CMS. The monthly amount varies by patient, county and severity of health status. Humana, in turn, allocates a majority of this amount to Metcare for all patients cared for by Metcare.

Metcare serves over 25,000 patients enrolled by Humana, Inc. in South and Central Florida. Metcare's Provider Service Network (PSN) operates predominantly as an affiliated model as contrasted with a staff model in which the physician practices are owned and operated by the risk provider. Under the Company's model, the physicians maintain their independence but are aligned with a professional staff that assists in providing high quality, cost effective health care. Metcare's PSN is comprised of 33 primary care physician practices, six of which the Company owns. The others are independent practices that are contracted with on a capitated-basis. Under these agreements, Metcare pays the physician a set amount per member, per month, to provide the necessary primary care services on a risk basis. The monthly amount is negotiated and is subject to change based on certain quality metrics under the Company's Partners In Quality (PIQ) program. In addition to primary care physicians, the Company's PSN contracts with specialists, ancillary service providers and hospitals. These providers deliver services to the Company's patients based on certain fee schedules and care requirements. Metcare has capitated (fixed cost) certain high volume specialties, averaging the cost on a per member, per month basis; the others are paid on a contractual fee-for-service basis.

Metropolitan does not pay or process any of the payments to its PSN physicians or other providers. All claims processing is handled directly by Humana. The Company does review and approve claims in advance of payment

(prospective payment review). Incorrect claims are identified and corrected prior to payment by the Company's claims suspense staff. Paid claims are reviewed again and errors are handled and recovered by Metcare's contestation staff. The Company regularly monitors and measures Humana's claims escrow pools, or allocations for claims incurred but not yet reported (IBNR), for accuracy and underfunding.

Metropolitan is certified as a Utilization Review Agent by Florida's Agency for Health Care Administration. Utilization review is a process whereby multiple data are analyzed and considered to ensure that appropriate health services are provided in a cost-effective manner. Factors include the risks and benefits of a medical procedure, the cost of providing those services, specific payer coverage guidelines, and historical outcomes of healthcare providers such as physicians and hospitals.

The Company has developed a proprietary care management model, Partners In Quality (PIQ), which was implemented in 2002. PIQ is based on the principle that optimal clinical outcomes depend on multiple factors including perceptions of care, efficient utilization of healthcare resources, evidence-based medical treatment and appropriate follow-up. This model is used to manage and compensate the Company's primary care physicians in caring for Metcare's patients. The PIQ program measures performance based on quality metrics including patient satisfaction, disease state management of high-risk, chronically ill patients, increased frequency of

Table of Contents

physician-patient encounters, and enhanced medical record documentation. Metropolitan believes this focus provides a competitive advantage as a provider service network.

Competition

The healthcare industry is highly competitive and is subject to continuing changes in the provisioning of services and the selection and compensation of providers. The Company competes with national, regional and local companies in providing its services. Metcare competes with other risk providers for Humana's business, and Humana competes with other HMOs in securing and serving patients in the Medicare Advantage program.

Growth Initiatives

Membership in Medicare Advantage programs (previously Medicare +Choice) has declined as a percentage of Medicare eligible lives over the last several years, principally the result of decreased funding which has negatively impacted plan benefits. Although the Company has seen growth in its membership through its expansion of its relationship with Humana, Metcare has experienced gradual attrition in membership commensurate with the industry. Net membership decreases from attrition were approximately 1,200 or 4.4% in 2003. The Company expects this trend to reverse with the passage of the Medicare Modernization Act in late 2003. With operations focused in Florida, the nation's second largest Medicare market, the Company expects incremental membership growth in its current markets. Among a number of sweeping changes to Medicare, the legislation is intended to substantially increase participation in Medicare Advantage through increased funding commitments. Beginning with an average increase of 10.6% in 2004, this stimulus allows plans to improve benefits and attract new enrollees. The Company's 2004 premium increases are approximately 9.8% in Daytona and 17.8% in South Florida, a significant portion of which will be utilized to enhance plan benefits. As well, Metcare expects that opportunities to expand into other Florida markets will develop as Humana and other Medicare HMOs grow their respective businesses.

The underlying economics of the Medicare Modernization Act may also provide sufficient incentive for companies such as Metcare to directly enter the Medicare Advantage business. The Company is currently evaluating its opportunities in Florida, particularly in underserved markets, and may file for its own Medicare HMO license in 2004. The decision to enter this business would necessarily be based on a number of factors including analysis of the opportunity, consideration of alternative strategies and availability of necessary capital.

Employees

As of December 31, 2003, the Company had approximately 100 full-time employees, of which 31 were employed at the Company's executive offices. No employees of the Company are covered by a collective bargaining agreement or are represented by a labor union. The Company considers its employee relations to be good.

Description of Property

Our offices are located at 250 Australian Avenue South, Suite 400, West Palm Beach, Florida where we occupy 13,211 square feet at a current monthly rent of \$15,700 pursuant to a lease expiring March 31, 2008.

The Company has a satellite office in Daytona Beach with 5,700 square feet and monthly rent of \$8,600. The lease expires September 30, 2006.

The managed care division leases 6 offices in Florida with an aggregate monthly rental of \$28,800 with expiration dates ranging from one to five years.

None of the Company's properties are leased from affiliates.

Legal Proceedings

The Company is a party to various claims arising in the ordinary course of business. Management believes that the outcome of these matters will not have a materially adverse effect on the financial position or the results of operations of the Company.

In June 2003, the Company was informed that the U.S. Attorneys' Office in Wilmington, Delaware was conducting an investigation of the Company. The Company fully cooperated with the U.S. Attorneys' Office and on February 9, 2004 the investigation was terminated.

Submission of Matters to a Vote of Security Holders

Table of Contents

No matter was submitted to a vote of the security holders, through the solicitation of proxies or otherwise, during the twelve months ended December 31, 2003.

Selected Financial Data

Set forth below is our selected historical consolidated financial data for the five fiscal years ended December 31, 2003. The selected historical consolidated financial data should be read in conjunction with our consolidated financial statements and accompanying notes.

	For the Years Ended December 31,				
	2003	2002	2001	2000*	1999
Net revenues	\$ 143,874,488	\$ 140,063,566	\$ 128,186,307	\$ 119,047,520	\$ 18,501,497
Income (Loss) from continuing Operations	\$ 5,861,303	\$ (13,865,800)	\$ 997,990	\$ 4,417,862	\$ (7,841,805)
Income (Loss) from continuing operations per share basic	\$ 0.17	\$ (0.46)	\$ 0.04	\$ 0.26	\$ (1.09)
Cash dividend declared					
Financial Position					
Total assets	\$ 9,223,729	\$ 10,158,911	\$ 17,379,262	\$ 11,159,834	\$ 11,944,747
Long term obligations, including current portion	\$ 2,983,576	\$ 5,603,370	\$ 1,821,705	\$ 1,664,961	\$ 9,370,948

* The financial data for 2000 includes the operations of Metlabs, Inc. which was discontinued in 2002.

** The financial data for the years ended 2003, 2002, 2001 and 2000 are presented on a calendar year with the Company's year-end being December 31. The financial data for the year ended 1999 is presented on a fiscal year with the Company's year-end being June 30.

Directors, Executive Officers, Promoters and Control Persons of the Registrant; Compliance with Section 16(A) of the Exchange Act.

As of the date of this filing, the directors, control persons and executive officers of the Company are as follows

Name	Age	Title
Michael M. Earley	48	President and Chief Executive Officer, Director
Debra A. Fimmel	42	Vice President and Chief Operating Officer, Director
David S. Gartner, CPA	46	Chief Financial Officer
Roberto L. Palenzuela, Esq.	40	General Counsel and Secretary
Karl Sachs, CPA	68	Director

Martin Harrison, M.D.	51	Director
Salomon E. Melgen, M.D.	50	Director

MICHAEL M. EARLEY, was appointed President and Chief Executive Officer on March 10, 2003 and previously served as a Director of the Company from June 2000 to March 2001. Mr. Earley has been an advisor to public and privately owned companies, acting in a variety of management roles since 1997. He was President of Collins Associates, an institutional money management firm,

Table of Contents

and a principal and owner of Triton Group Management, Inc., which provided financial and management advisory services to a variety of clients. From 1986 to 1997, he served in a number of senior management roles including CEO and CFO of Intermark, Inc. and Triton Group Ltd.; both publicly traded diversified holding companies. Mr. Earley received undergraduate degrees in Accounting and Business Administration from the University of San Diego. From 1978 to 1983, he was an audit and tax staff member of Ernst & Whinney.

DEBRA A. FINNEL, Vice President and Chief Operating Officer has been associated with the Company since January 1999. She has twenty years of healthcare experience in the South Florida market, specializing in managed care and risk contracting, including five years as Regional Director with FamilyCare, Inc., the largest affiliate of IMC, Florida's first Medicare+Choice HMO. Prior to joining the Company, Ms. Finnel was President and Chief Operating Officer of Advanced HealthCare Consultants, Inc., which managed and owned physician practices in multiple states and provided turnaround consulting to managed care providers, MSOs, IPAs and hospitals. She also has extensive experience in provider contracting, claims administration and customer service. Ms. Finnel has had an affiliated provider relationship with Humana Medical Plans since their inception in the Florida market in 1986 and has developed strong relationships with many senior healthcare executives throughout Florida, as well as state and federal government.

DAVID S. GARTNER, CPA joined the Company in November 1999 as its Chief Financial Officer. He has over twenty years experience in accounting and finance, including thirteen years of specialization in the healthcare industry. Previously, Mr. Gartner served for two years as Chief Financial Officer of Medical Specialists of the Palm Beaches, Inc., a large Palm Beach County multi-practice, multi-specialty group of 40 physicians. Prior to Medical Specialists, he held the position of Chief Financial Officer at National Consulting Group, Inc., a treatment center licensed for 140 inpatient beds in New York and Florida, from 1991 to 1998. Mr. Gartner is a member of the American Institute of Certified Public Accountants and is a graduate of the University of Buffalo, where he received his BS in Accounting.

ROBERTO L. PALENZUELA, ESQ. was appointed General Counsel and Secretary in March of 2004. Mr. Palenzuela served as General Counsel and Secretary of Continucare Corporation from May 2002 through March 2004. From 1994 to 2003, Mr. Palenzuela served as an officer and director of Community Health Plan of the Rockies, Inc., a health maintenance organization based in Denver, Colorado. Community Health Plan of the Rockies, Inc. filed for protection under Chapter 11 of the federal bankruptcy laws on November 15, 2002, and was released from Chapter 11 on December 16, 2002. From March 1999 through June 2001, Mr. Palenzuela served as General Counsel of Universal Rehabilitation Centers of America, Inc. (n/k/a Universal Medical Concepts, Inc.), a physician practice management company.

DR. MARTIN HARRISON was appointed as a Director of the Company in November 2000. He served as an advisor to the Board for the past year. He has been practicing medicine in South Florida and specializes in preventive and occupational medicine. Dr. Harrison completed his undergraduate training at the University of Illinois and postgraduate and residency training at Johns Hopkins University, as well as his Masters in Public Health. Dr. Harrison has also been on the Faculty of both the University and Medical School. He is currently the owner of H30, Inc. a privately held Research & Biomedical Company.

DR. SALOMON E. MELGEN was appointed as a director of the Company in September 2002. He is a Board Certified Ophthalmologist and the founding Director of Vitreo-Retinal Consultants, specializing in diseases and surgery of the vitreous and retina. He has participated in the research and co-authorship of many published medical reports. Dr. Melgen was accepted as a Fellow of Vitreoretinal Diseases at Harvard Medical School, Massachusetts Eye and Ear Infirmary, Eye Research Institute and Retina Associates in Boston, Massachusetts. He is a Director of the American Board of Eye Surgery and is a clinical scientific associate at The Schepens Eye Research Institute, Harvard Medical School. Dr. Melgen has been awarded the highest honor from the government of the Dominican Republic for

his charitable work.

KARL SACHS, CPA rejoined the Board of Directors in September 2002 after previously serving as a Director of the Company from March 1999 to December 2001. He is a founding partner of the Miami-based public accounting firm of Sachs & Focaracci, P.A. A certified public accountant for more than thirty years, Mr. Sachs is a member of the American Institute of Certified Public Accountants, Personal Financial Planning and Tax Sections; Florida Institute of Certified Public Accountants; and the National Association of Certified Valuation Analysts. The firm of Sachs & Focaracci, P.A. serves the financial and tax needs of its diverse clients in addition to providing litigation support services. Mr. Sachs is a qualified litigation expert for the U.S. Federal District Court, U.S. District Court, U.S. Bankruptcy Court and Circuit Courts of Dade and Broward Counties and has previously served as an auditor for the Internal Revenue Service. He is a graduate of the University of Miami where he received his BS in Business Administration.

Board of Directors

Each director is elected at the Company's annual meeting of shareholders and holds office until the next annual meeting of stockholders, or until the successors are elected and qualified. At present, the Company's bylaws provide for not less than one director. Currently, there are five directors in the Company. The bylaws permit the Board of Directors to fill any vacancy and such director may serve until the next annual meeting of shareholders or until his successor is elected and qualified. Officers are elected by the Board of

Table of Contents

Directors and their terms of office are, except to the extent governed by employment contracts, at the discretion of the Board. There are no family relations among any officers or directors of the Company. The officers of the Company devote full time to the business of the Company. In 2003, the Board of Directors held sixteen meetings and there were no votes by Unanimous Written Consent.

The Board has adopted a Code of Business Conduct and Ethics, a copy of which is attached as an exhibit.

Board Committees

The Company has two active committees in 2004, the Audit & Finance Committee and the Executive & Compensation Committee. All actions by these committees shall be subject to the specific directions of the Board of Directors.

The Audit Committee consists of Mr. Sachs, Dr. Melgen and Dr. Harrison. The Audit Committee selects the independent auditors; reviews the results and scope of the audit and other services provided by the Company's independent auditors and reviews and evaluates the Company's internal control functions. As an advisory function of the committee, members also participate in financings, review budgets prior to presentation to the Board of Directors and review budget vs. actual reports. The board of directors has determined that Mr. Sachs is the audit committee financial expert, as such term is defined under federal securities law, and is independent. Mr. Sachs is an expert by virtue of his extensive career in the financial and accounting business.

The Executive and Compensation Committee may exercise the power of the Board of Directors in the management of our business and affairs at any time when the Board of Directors is not in session. The Executive Committee shall, however, be subject to the specific directions of the Board of Directors. The committee also makes recommendations to the Board of Directors regarding the compensation for our executive officers and consultants. It is currently composed of Dr. Harrison, Mr. Sachs and Dr. Melgen. All actions of the Executive Committee require a unanimous vote.

Compensation of Directors

The Company reimburses all Directors for their expenses in connection with their activities as Directors of the Company. The Directors make themselves available to consult with the Company's management. Currently, two of the five Directors of the Company are also employees of the Company and do not receive additional compensation for their services as Directors. A compensation and stock option agreement has been adopted for the Company's outside Directors in the amount of \$36,000 per year, paid quarterly. All outside directors have received 40,000 options upon joining the Board, of which 20,000 vest immediately and the remaining 20,000 vests after one year. These options are priced at the market value of the effective date of board membership.

Table of Contents**Executive Compensation.**

The following tables present information concerning the cash compensation and stock options provided to the Company's Chief Executive Officer and each additional executive officer whose total annualized compensation exceeded \$100,000 for the year ended December 31, 2003.

**SUMMARY COMPENSATION TABLE
ANNUAL COMPENSATION**

Name and Principal Position	Fiscal Year	Salary (\$)	Other Annual Compensation Bonus (\$)	Securities Underlying Options Compensation (S)	All other SARs(\$)	Compensation
Michael M. Earley* President, and Chief Executive Officer	2003	117,821				117,821
Fred Sternberg* Chairman of the Board, President, CEO	2003	68,778	9,600			78,378
	2002	309,736	9,600			319,336
	2001	224,905	9,600			234,505
Debra A. Finnel Vice President and Chief Operating Officer	2003	249,026	118,000			367,026
	2002	249,849	18,000			267,849
	2001	227,884	18,000			245,884
David S. Gartner, CPA Secretary and Chief Financial Officer	2003	143,767	6,000			149,767
	2002	120,000	6,000			126,000
	2001	119,423	6,000			125,423

* Fred Sternberg resigned as President & CEO and Michael Earley assumed the positions of the Company's President & CEO effective March 10, 2003

Options granted in the Year Ended December 31, 2003 to Executives*

Name	Number of Securities Underlying Options/ SARs Granted	% of Total Options/ SARs Granted to Employees in Fiscal Year	Exercise of Base Price (\$/Share)	Expiration Date
Michael M. Earley	116,667	5.7%	\$0.35	12/31/08
Michael M. Earley	116,667	5.7%	\$0.35	12/31/09
Michael M. Earley	116,666	5.7%	\$0.35	12/31/10
Debra A. Finnel	350,000	17.2%	\$0.35	9/22/08
David S. Gartner	180,000	8.8%	\$0.35	9/22/08

*See discussion of Fred Sternberg termination agreement.

There were 880,000 options granted to executive employees for the year ended December 31, 2003, none for the year ended December 31, 2002 and 300,000 for the year ended December 31, 2001.

Aggregated Fiscal Year-End Option Value Table

The following table sets forth certain information concerning unexercised stock options as of December 31, 2003. No stock appreciation rights were granted or are outstanding.

Name	Number Of Unexercised Options Held at 12/31/03			Value Of Unexercised In-the-Money Options at 12/31/03 (1)	
	Shares Exercisable	Shares Acquired On Exercise	Shares Unexercisable	Exercisable	Unexercisable
Michael M. Earley	181,667	181,667	233,333	\$ 66,233	\$95,667
Debra A. Finnel	700,000	700,000	100,000	\$182,500	
David S. Gartner	180,000	180,000		\$ 73,800	

Table of Contents

- (1) The closing sale price of the Common Stock on December 31, 2003 as reported by OTCBB was \$0.76 per share. Value is calculated by multiplying (a) the difference between \$0.76 and the option exercisable price by (b) the number of shares of Common Stock underlying.

Employment Agreements

FRED STERNBERG

In January 2000, the Company entered into an employment agreement, subsequently amended, with Fred Sternberg, the Company's President, Chief Executive Officer and a director. The term of the agreement was for five years from the effective date. The annual salary under the Agreement was \$150,000. Effective April 1, 2001, the salary was increased to \$250,000 per year. Additionally, Mr. Sternberg was granted options to purchase 300,000 shares of Common Stock at \$0.30 per share and options to purchase 360,000 shares of Common stock at \$0.50 per share upon the signing of the Agreement. Additional longevity options were granted at the rate of 25,000 options per year of employment at a price of \$1.00 per share. The Agreement also provided for an additional 700,000 options at \$0.75 per share vesting on various dates over the life of the Contract.

The Agreement also provided, among other things, for (i) participation in any profit-sharing or retirement plan and in other employee benefits applicable to employees and executives of the Company; (ii) an automobile allowance of \$800 per month and fringe benefits commensurate with the duties and responsibilities of Mr. Sternberg and (iii) benefits in the event of death or disability. The Agreement also contains certain non-disclosure and non-competition provisions.

Under the terms of the Agreement, the Company could terminate the employment of Mr. Sternberg either with or without cause. If the Company without good cause terminated the Agreement, the Company would be obligated to continue to pay Mr. Sternberg's salary and any current and future bonuses that would have been earned under the agreement. Mr. Sternberg would also be entitled to all stock options earned or not yet earned through the full term of the Agreement.

Mr. Sternberg resigned as President and Chief Executive Officer effective March 10, 2003. The Company and Sternberg reached agreement with respect to the terms and conditions of the settlement of Mr. Sternberg's employment agreement, which ran through December 2004. The total settlement, which was substantially less than what was due under the remainder of Sternberg's contract, provides that Sternberg will receive consideration including \$180,000 payable over the twelve months ending June 30, 2004, certain insurance benefits and options to purchase 300,000 of the Company's common stock at \$0.46, the current market price at date of grant.

MICHAEL M. EARLEY

Effective January 1, 2004, the Company entered into an employment agreement with Michael M. Earley, President and Chief Executive Officer. The term of the agreement is for one year and shall automatically renew on the anniversary date. The agreement calls for an annual salary of \$250,000, a monthly auto allowance of \$800 and certain other fringe benefits commensurate with Mr. Earley's responsibilities. In addition, the agreement also calls for discretionary annual increases, bonuses and options as determined by the Company's Board of Directors.

DEBRA A. FINNEL

In January 2001, the Company entered into an employment agreement with Debra A. Finnel, Vice President and Chief Operating Officer. The term of the agreement is five years and calls for an annual salary of \$225,000, which was increased to \$250,000 on July 1, 2001. Ms. Finnel is also eligible to receive a discretionary bonus and was granted options to purchase 300,000 shares of Common Stock at \$1.00 per share with vesting over three years. The

Agreement also calls for an automobile allowance of \$1,500 per month and fringe benefits commensurate with Ms. Finnel's responsibilities as well as certain non-compete provisions.

Compensation Committee Interlocks and Insider Participation

During the year ended December 31, 2003, the following individuals served as members of the Company's compensation committee; Dr. Martin Harrison, Dr. Salomon Melgen and Karl Sachs.

With the exception of Dr. Martin Harrison and Dr. Salomon Melgen (as disclosed in Item 13), none of the members of the Compensation Committee were, or have ever been, employed by the Company or received any compensation from the Company other than in their capacity as director.

Board Compensation Committee Report on Executive Compensation

During the year ended December 31, 2003, the following individuals served as members of the Company's compensation committee; Dr. Martin Harrison, Dr. Salomon Melgen and Karl Sachs. In addition, Randolph Pohlman, Ph.D. served on the committee from January 1, 2003 to March 5, 2003.

Table of Contents

The compensation committee is responsible for the review and negotiation of all executive employment agreements, incentive bonuses and equity compensation. In 2003, the salaries of the COO and former CEO were determined by contracts that were negotiated in prior fiscal years as discussed above. In early 2004, the committee negotiated a contract with Michael M. Earley, President and CEO, as discussed above. Incentive bonuses and equity compensation paid to executives are at the sole discretion of the board of directors and the compensation committee and, for the fiscal year ended December 31, 2003, \$100,000 in incentive bonuses and 880,000 stock options were granted to executives.

The following table sets forth certain information regarding the Company's Common Stock beneficially owned at April 30, 2004 (i) by each person who is known by the Company to own beneficially 5% or more of the Company's common stock; (ii) by each of the Company's directors; and (iii) by all executive officers and directors as a group.

Name of Beneficial Owner	Amount of Beneficial Ownership	Percentage of Class
Martin Harrison, M.D. (1)	5,525,100	12.09%
Karl Sachs (2)	808,503	1.77
Debra Finnel (3)	750,000	1.64
David S. Gartner (4)	280,000	0.61
Salomon Melgen, M.D	1,014,127	2.22
Michael M. Earley (5)	201,607	0.44
Directors and Executive Officers as a Group (6 persons)	8,579,337	18.78

- (1) Includes (1) 4,464,920 shares held by Dr. Harrison, (2) 900,000 shares held by H30, Inc., a corporation which Dr. Harrison is a Director, (3) 40,000 shares issuable upon exercise of options at a price of \$0.91 until November 2, 2006 and (4) 70,000 shares issuable upon exercise of options at a price of \$0.70 until December 19, 2008. Does not include 56,000 shares issuable upon exercise of options at prices ranging from \$6.938 to \$7.938 per share with expirations from April 2004 until April 18, 2005.
- (2) Includes 172,500 shares issuable upon the exercise of options at a price of \$0.35, expiring in September 2008 and 57,500 shares issuable upon the exercise of options at a price of \$0.35 that expiring in December 2008.
- (3) Includes (1) 50,000 shares held by Debra Finnel, (2) 150,000 shares issuable upon the exercise of options at \$0.50 per share, expiring between October 2005 and October 2007, (3) 200,000 shares issuable upon the exercise of options at a price of \$1.00, expiring between 1/1/07 and 1/1/08 and (4) 350,000 shares issuable upon the exercise of options at a price of \$0.35, expiring in September of 2008. Does not include 100,000 shares issuable upon the exercise of options at a price of \$1.00 that have not yet vested.
- (4) Includes 180,000 shares issuable upon the exercise of options at a price of \$0.35, expiring in September 2008.
- (5) Includes (1) 40,000 shares issuable upon the exercise of options at a price of \$0.30 per share, expiring between June 2005 and June 2006, (2) 25,000 shares issuable upon the exercise of options at a price of \$2.00 per share, expiring in September 2005 and (3) 116,667 shares issuable upon the exercise of options at a price of \$0.35 per share, expiring in December 2008. Does not include 233,333 shares issuable upon the exercise of options at a price of \$0.35 per share that have not yet vested.

Table of Contents**Equity Compensation Plan**

The following table details information regarding the Company's existing equity compensation plans as of December 31, 2003:

	(a)	(b)	(c)
	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
Equity compensation plans Approved by security holders	2,000,000	\$ 0.43	
Equity compensation plans not Approved by security holders	8,253,242	\$ 1.22	
Total	10,253,242		

During 2003, 2,750,400 options were issued to employees and directors of the Company upon board approval. Of these, 971,867 were issued without the approval of security holders.

Certain Relationships and Related Transactions.

The Company, for the current year ending December 31, 2003, paid a company owned by Dr. Salomon Melgen, a shareholder and director, \$393,000 for services rendered as a physician in the Company's provider network. The fees paid were usual and customary for the services provided.

The Company, for the current year ending December 31, 2003, paid Dr. Martin Harrison, a shareholder and director, \$25,000 for consulting services.

All future transactions between the Company and any officer, director or 5% shareholder will be on terms no less favorable than could be obtained from independent third parties and will be approved by a majority of the independent disinterested directors of the Company.

Table of Contents

DESCRIPTION OF SECURITIES

As of April 30, 2004, we had authorized 80,000,000 shares of par value \$0.001 common stock, with 45,712,960 shares issued and outstanding. Additionally, we have authorized 10,000,000 shares of preferred stock, with 5,000 shares issued and outstanding.

Common Stock

The holders of Common Stock are entitled to one vote for each share held of record on all matters to be voted on by stockholders. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. The holders of Common Stock are entitled to receive dividends when, as and if declared by the Board of Directors out of funds legally available therefore. In the event of our liquidation, dissolution or winding up, the holders of Common Stock are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision has been made for each class of stock, if any, having preference over the Common Stock. Holders of shares of Common Stock, as such, have no conversion, preemptive or other subscription rights, and there are no redemption provisions applicable to Common Stock. All of the outstanding shares of Common Stock are, and the shares of Common Stock offered hereby, will be duly authorized, validly issued, fully paid and non-assessable.

Preferred Stock

We are authorized to issue 10,000,000 shares of Preferred Stock with such designation, rights and preferences, as may be determined from time to time by the Board of Directors. Accordingly, the Board of Directors is empowered, without stockholder approval, to issue Preferred Stock with dividend, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the holders of the Common Stock. In the event of issuance, the Preferred Stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control.

We have designated a Series A class of preferred stock and a Series B class of preferred stock. A summary of their material terms, rights and preferences are the following:

Series A

We have designated 9,993,000 shares of our preferred stock as Series A preferred stock, par value \$.001. There are currently 5,000 Series A preferred shares issued and outstanding. Each share of Series A preferred stock has a stated value of \$100 and pays dividends equal to 10% of the stated value per annum. At December 31, 2003, the aggregate and per share amounts of cumulative dividend arrearages were approximately \$316,667 (\$63 per share).

Each share of Series A preferred stock is convertible into shares of common stock at the option of the holder at the lesser of 85% of (1) the average closing bid price of the common stock for the ten trading days immediately preceding the conversion or (2) \$6.00. We have the right to deny conversion of the Series A preferred stock, at which time the holder shall be entitled to receive additional cumulative dividends at 5% per annum in addition to the initial dividend rate of 10% per annum.

In addition, we have the right, exercisable at any time upon 10 trading days notice to the holders of the Series A preferred stock given at any time after the expiration of two years after the date of issuance to redeem all or any portion of the shares of Series A preferred stock which have not previously been converted or redeemed, at a price equal to 105% of the product of (1) the number of shares of preferred stock then held by the holder, and (2) the stated value.

In the event of any liquidation, dissolution or winding up of our company, holders of the Series A preferred stock are entitled to receive a liquidating distribution before any distribution may be made to holders of our common stock and other Series of our preferred stock.

The Series A preferred share holders have no voting rights, except as provided under Florida law.

Series B

We have designated 7,000 shares of our preferred stock as Series B preferred stock, with a stated value of \$1,000 per share. During the year ended June 30, 1998, 1,200 shares of Series B preferred stock were issued, however there are currently no Series B shares outstanding. Holders of the Series B preferred stock are entitled to receive, whether declared or not, cumulative dividends equal to 5% per annum. Each share of Series B preferred stock is convertible into such number of fully paid and nonassessable shares of common stock as is determined by dividing the stated value by the conversion price. The conversion price shall be the lesser of the market price, as defined or \$4.00. From September 1998 to October 1999, all of our outstanding Series B preferred shares were converted into 3,597,305 shares of our common stock at various prices. The Series B preferred shares do not contain voting rights, except as provided under Florida law.

Table of Contents**Transfer Agent**

The Transfer Agent for our shares of Common Stock is Florida Atlantic Stock Transfer, Tamarac, Florida

SELLING SECURITY HOLDERS

This prospectus relates in part to the registration of shares of our common stock underlying certain convertible securities held by various parties listed below. We will not receive any proceeds from the sale of the shares by the selling shareholders. The selling shareholders may resell the shares they acquire by means of this prospectus from time to time in the public market. The costs of registering the shares offered by the selling shareholders are being paid by us. The selling shareholders will pay all other costs of the sale of the shares offered by them.

Private Placement

In February 2004, we issued an aggregate of 5,004,999 shares of common stock to 24 accredited and 1 non-accredited investors, for \$0.60 per share. We received \$3,003,000 in proceeds from the sale of these shares. The shares of common stock were issued under the exemption from registration provided by Section 4(2) of the Securities Act. The investors received current information about the Company and had the opportunity to ask questions about the Company. The investors purchased the shares for investment purposes and the shares they received were marked with the appropriate restrictive legend.

Michael Rosenbaum

In March 2004, Michael Rosenbaum exercised his option to convert a 6% Convertible Debenture dated October 1, 2002 in the amount of \$168,000 to stock. The stock was converted at \$0.43 per shares and 390,698 shares of common stock were issued.

In March 2004, we issued 220,000 shares of common stock to Michael Rosenbaum for \$0.60 per share. The shares of common stock were paid for by the delivery to the Company of a Promissory Note issued by the Company to Michael Rosenbaum in the principal amount of \$132,000 marked Paid in Full. The shares of common stock were issued under the exemption from registration provided by Section 4(2) of the Securities Act.

Global Capital Funding Group, L.P.

In March 2004, 100,000 shares of common stock were issued to Global Capital Funding Group, L.P. as a fee in connection with an extension of a Promissory Note that was due May 24, 2004. The extension provides for repayment of \$1.2 million over a two-year period with monthly payments in the amount of \$50,000. A final balloon payment of the remaining unpaid balance plus accrued interest, if any, is due on May 24, 2006.

Name of Shareholder	Common Shares Offered in the Offering		Common Shares Owned After Offering	
	Number	Percentage	Number	Percentage
Global Capital Funding Group, L.P. (1)	100,000	*	0	*
Michael Rosenbaum	610,698	1.34%	0	*

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

Active Investors II (2)	850,000	1.86%	0	*
Active Investors III (2)	850,000	1.86%	0	*
Robert Arkin	330,000	*	0	*
Pamela O Connor	330,000	*	0	*
Michael Cahr	333,333	*	0	
Michelle Cahr	83,333	*	0	*
Red and Kathy Scott Trust	200,000	*	0	*
PJC & Associates, Ltd. (3)	100,000	*	0	*
Avenue Asset Partners (4)	50,000	*	0	*
C. Richard Stafford	50,000	*	0	*
Mitchell L. Silverman	83,333	*	0	*
Barry N. Wish	150,000	*	0	*
Daniel J. Kraus	50,000	*	0	*
Salomon Melgen, M.D. (6)	500,000	1.09%	0	*
Karl M. Sachs & Donna B. Sachs (7)	80,000	*	0	*

Table of Contents

Name of Shareholder	Common Shares Offered in the Offering		Common Shares Owned After Offering	
	Number	Percentage	Number	Percentage
Allen J. Rapoport	40,000	*	0	*
Luis Rodriguez-Molina	80,000	*	0	*
Robert S. Lamont & Paula T. Lamont	30,000	*	0	*
Ellen Bellet Gelberg & Stanley S. Gelberg	30,000	*	0	*
Lisa Nora Interian & Alberto Interian	15,000	*	0	*
Jan S. Neiman & Marlene L. Neiman	30,000	*	0	*
Berman & Berman, P.A. (5)	10,000	*	0	*
Ralph L. Focaracci	80,000	*	0	*
Roger W. Miller	150,000	*	0	*
Jan Loeb	500,000	1.09%	0	*

* Represents less than 1% of the issued and outstanding shares as of April 30,2004.

- (1) Lewis N. Lester has investment and voting control over the shares held by Global Capital Funding Group, L.P.
- (2) Carl N. Singer has investment and voting control over the shares held by Active Investors II and Active Investors III.
- (3) Red Scott has investment and voting control over the shares held by PJC & Associates, Ltd.
- (4) George Parry has investment and voting control over the shares held by Avenue Asset Partners.
- (5) David Berman has investment and voting control over the shares held by Berman & Berman, P.A.
- (6) Director
- (7) Karl M. Sachs is a Director of the Company.

PLAN OF DISTRIBUTION

The selling security holders and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling security holders may use any one or more of the following methods when selling shares:

ordinary brokerage transactions
and transactions in which the
broker-dealer solicits purchasers;

block trades in which the
broker-dealer will attempt to sell
the shares as agent but may
position and resell a portion of the
block as principal to facilitate the

transaction;

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

an exchange distribution in accordance with the rules of the applicable exchange;

privately negotiated transactions;

short sales;

broker-dealers may agree with the selling security holders to sell a specified number of such shares at a stipulated price per share;

a combination of any such methods of sale; and

any other method permitted pursuant to applicable law.

The selling security holders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus. Broker-dealers engaged by the selling security holders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling security holders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling security holders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved.

The selling security holders may from time to time pledge or grant a security interest in some or all of the shares or common stock or warrants owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus, or under an amendment to this prospectus

Table of Contents

under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling security holders to include the pledgee, transferee or other successors in interest as selling security holders under this prospectus.

The selling security holders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The selling security holders and any broker-dealers or agents that are involved in selling the shares may be deemed to be underwriters within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The selling security holders have informed us that they do not have any agreement or understanding, directly or indirectly, with any person to distribute the common stock.

We are required to pay all fees and expenses incident to the registration of the shares. We have agreed to indemnify the selling security holders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

SHARES ELIGIBLE FOR FUTURE SALE

As of April 30, 2004, we have 45,711,008 shares of common stock issued and outstanding. This does not include shares that may be issued upon exercise of options or warrants.

We cannot predict the effect, if any, that market sales of common stock or the availability of these shares for sale will have on the market price of our shares from time to time. Nevertheless, the possibility that substantial amounts of common stock may be sold in the public market could negatively damage and affect market prices for our common stock and could damage our ability to raise capital through the sale of our equity securities.

INDEMNIFICATION OF OFFICERS AND DIRECTORS

The Florida Business Corporation Act (the Corporation Act) permits the indemnification of directors, employees, officers and agents of Florida corporations. Our Articles of Incorporation (the Articles) and Bylaws provide that we shall indemnify our directors and officers to the fullest extent permitted by the Corporation Act.

The provisions of the Corporation Act that authorize indemnification do not eliminate the duty of care of a director, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Florida law. In addition, each director will continue to be subject to liability for (a) violations of criminal laws, unless the director had reasonable cause to believe his conduct was lawful or had no reasonable cause to believe his conduct was unlawful, (b) deriving an improper personal benefit from a transaction, (c) voting for or assenting to an unlawful distribution and (d) willful misconduct or conscious disregard for our best interests in a proceeding by or in the right of a shareholder. The statute does not affect a director's responsibilities under any other law, such as the Federal securities laws.

The effect of the foregoing is to require us to indemnify our officers and directors for any claim arising against such persons in their official capacities if such person acted in good faith and in a manner that he reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding,

had no reasonable cause to believe his conduct was unlawful.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers or persons in control pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the act and is therefore unenforceable.

LEGAL MATTERS

The validity of the securities offered by this prospectus will be passed upon for us by Adorno & Yoss, P.A., 350 East Las Olas Boulevard, Suite 1700, Fort Lauderdale, FL 33301, Florida.

EXPERTS

The consolidated balance sheets as of December 31, 2003 and 2002, and the related consolidated statements of operations, changes in stockholders' equity (accumulated deficit), and cash flows for each of the three years in the period ended December 31, 2003, are included herein in reliance on the reports of Kaufman, Rossin & Co., P.A., independent accountants, given on the authority of that firm as experts in accounting and auditing.

ADDITIONAL INFORMATION

We have filed with the SEC the registration statement on Form S-1 under the Securities Act for the common stock offered by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information in the registration statement and the exhibits filed with it, portions of which have been omitted as permitted by SEC rules and regulations. For further information

Table of Contents

concerning us and the securities offered by this prospectus, we refer to the registration statement and to the exhibits filed with it. Statements contained in this prospectus as to the content of any contract or other document referred to are not necessarily complete. In each instance, we refer you to the copy of the contracts and/or other documents filed as exhibits to the registration statement, and these statements are qualified in their entirety by reference to the contract or document.

The registration statement, including all exhibits, may be inspected without charge at the SEC's Public Reference Room at 450 Fifth Street, N.W. Washington, D.C. 20549, and at the SEC's regional offices located at the Woolworth Building, 233 Broadway, New York, New York 10279 and Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661. Copies of these materials may also be obtained from the SEC's Public Reference at 450 Fifth Street, N.W., Room 1024, Washington D.C. 20549, upon the payment of prescribed fees. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.

The registration statement, including all exhibits and schedules and amendments, has been filed with the SEC through the Electronic Data Gathering, Analysis and Retrieval system, and are publicly available through the SEC's Web site located at <http://www.sec.gov>.

Table of Contents

**METROPOLITAN HEALTH
NETWORKS, INC. AND SUBSIDIARIES**

CONSOLIDATED FINANCIAL STATEMENTS

CONTENTS

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2004	
Condensed Consolidated Balance Sheets	F-2
Condensed Consolidated Statements of Operations	F-3
Condensed Consolidated Statements of Cash Flows	F-4
Notes to Condensed Consolidated Financial Statements	F-5
CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2003, 2002 AND 2001	
Independent Auditors' Report	F-11
Balance Sheets	F-12
Statements of Operations	F-13
Statements of Changes in Stockholders' Equity/ (Deficiency in Assets)	F-14
Statements of Cash Flows	F-16
Notes to Financial Statements	F-17

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS**

	March 31, 2004	December 31, 2003
	(Unaudited)	(Audited)
	<hr/>	<hr/>
ASSETS		
CURRENT ASSETS		
Cash and equivalents	\$ 1,366,647	\$ 2,176,204
Accounts receivable, net of allowance	2,121,067	2,138,690
Inventory	256,002	304,248
Other current assets	810,263	833,112
	<hr/>	<hr/>
TOTAL CURRENT ASSETS	4,553,979	5,452,254
CERTIFICATES OF DEPOSIT restricted	1,000,000	1,000,000
PROPERTY AND EQUIPMENT, net	625,039	659,682
GOODWILL, net	1,992,133	1,992,133
OTHER ASSETS	102,699	119,660
	<hr/>	<hr/>
TOTAL ASSETS	\$ 8,273,850	\$ 9,223,729
	<hr/>	<hr/>
LIABILITIES AND STOCKHOLDERS EQUITY/(DEFICIENCY IN ASSETS)		
CURRENT LIABILITIES		
Advances from HMO	\$	\$ 164,536
Accounts payable	990,677	1,756,347
Accrued expenses	752,686	1,413,195
Current maturities of capital lease obligations	69,419	104,315
Current maturities of long-term debt	416,547	975,169
Payroll taxes payable	234,199	3,408,736
	<hr/>	<hr/>
TOTAL CURRENT LIABILITIES	2,463,528	7,822,298
CAPITAL LEASE OBLIGATIONS		3,092
LONG-TERM DEBT	802,436	1,901,000
	<hr/>	<hr/>
TOTAL LIABILITIES	3,265,964	9,726,390
	<hr/>	<hr/>
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS EQUITY/(DEFICIENCY IN ASSETS)		
Preferred stock, par value \$.001 per share; stated value \$100 per share; 10,000,000 shares authorized; 5,000 issued and	500,000	500,000

outstanding

Common stock, par value \$.001 per share; 80,000,000 shares authorized; 45,692,748 and 38,527,699 issued and outstanding,

respectively	45,693	38,527
Additional paid-in capital	35,419,206	31,343,887
Accumulated deficit	(30,793,524)	(32,238,333)
Common stock issued for services to be rendered	(163,489)	(146,742)

TOTAL STOCKHOLDERS EQUITY/(DEFICIENCY IN ASSETS)	<u>5,007,886</u>	<u>(502,661)</u>
--	------------------	------------------

TOTAL LIABILITIES AND STOCKHOLDERS EQUITY/(DEFICIENCY IN ASSETS)	<u>\$ 8,273,850</u>	<u>\$ 9,223,729</u>
--	---------------------	---------------------

See accompanying notes unaudited

F-2

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

	For the three months ended March 31,	
	2004	2003
	(Unaudited)	(Unaudited)
	<hr/>	<hr/>
REVENUES	\$38,543,196	\$36,876,548
	<hr/>	<hr/>
EXPENSES		
Direct medical costs	33,237,803	31,841,794
Payroll, payroll taxes and benefits	1,938,774	1,899,372
Medical supplies	511,379	428,586
Depreciation and amortization	122,523	167,481
Rent and leases	275,909	231,981
Consulting expense	142,191	407,275
General and administrative	702,257	569,011
	<hr/>	<hr/>
TOTAL EXPENSES	36,930,836	35,545,500
	<hr/>	<hr/>
INCOME BEFORE OTHER INCOME (EXPENSE)	1,612,360	1,331,048
	<hr/>	<hr/>
OTHER INCOME (EXPENSE):		
Interest and penalty expense	(154,522)	(386,370)
Other income	32,929	20,014
	<hr/>	<hr/>
TOTAL OTHER INCOME (EXPENSE)	(121,593)	(366,356)
	<hr/>	<hr/>
INCOME FROM CONTINUING OPERATIONS	1,490,767	964,692
	<hr/>	<hr/>
DISCONTINUED OPERATIONS:		
Loss from operations of discontinued business segments	(45,958)	(248,995)
	<hr/>	<hr/>
NET INCOME	\$ 1,444,809	\$ 715,697
	<hr/>	<hr/>
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	41,722,527	32,273,745

	<u> </u>	<u> </u>
INCOME FROM CONTINUING OPERATIONS:		
Basic	\$ 0.03	\$ 0.03
	<u> </u>	<u> </u>
Diluted	\$ 0.03	\$ 0.03
	<u> </u>	<u> </u>
LOSS FROM DISCONTINUED OPERATIONS:		
Basic	\$	\$ (0.01)
	<u> </u>	<u> </u>
Diluted	\$	\$ (0.01)
	<u> </u>	<u> </u>
NET EARNINGS PER SHARE:		
Basic	\$ 0.03	\$ 0.02
	<u> </u>	<u> </u>
Diluted	\$ 0.03	\$ 0.02
	<u> </u>	<u> </u>

See accompanying notes unaudited

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

	For the three months ended March 31,	
	2004	2003
	(Unaudited)	(Unaudited)
	<hr/>	<hr/>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net income	\$ 1,444,809	\$ 715,697
	<hr/>	<hr/>
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:		
Depreciation and amortization	147,156	167,481
Amortization of discount on notes payable	66,949	46,541
Stock issued for interest and late fees	578	80,000
Stock issued for compensation and services	36,000	41,500
Amortization of securities issued for professional services		64,352
Changes in assets and liabilities:		
Accounts receivable, net	17,623	99,417
Inventory	48,246	28,377
Other current assets	22,849	(183,527)
Net change in operating assets held for sale		(318,795)
Other assets	(15,000)	(22,739)
Accounts payable and accrued expenses	(1,426,179)	232,605
Payroll taxes payable	(3,174,537)	216,072
	<hr/>	<hr/>
Total adjustments	(4,276,315)	451,284
	<hr/>	<hr/>
Net cash (used in)/provided by operating activities	(2,831,506)	1,166,981
	<hr/>	<hr/>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of restricted certificates of deposit		(50,000)
Capital expenditures	(36,632)	(73,122)
	<hr/>	<hr/>
Net cash (used in) investing activities	(36,632)	(123,122)
	<hr/>	<hr/>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Borrowings on notes payable		501,199
Repayments on notes payable	(709,135)	(661,648)
Repayments on capital lease obligations	(37,988)	(53,865)

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

Net proceeds from issuance of common stock	2,970,240	
Repayments to HMO	<u>(164,536)</u>	<u>(789,708)</u>
Net cash provided by/(used in) financing activities	<u>2,058,581</u>	<u>(1,004,022)</u>
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS	(809,557)	39,837
CASH AND EQUIVALENTS BEGINNING	<u>2,176,204</u>	<u>399,614</u>
CASH AND EQUIVALENTS ENDING	<u>\$ 1,366,647</u>	<u>\$ 439,451</u>

See accompanying notes unaudited

F-4

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)**

NOTE 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. Operating results for the three months ended March 31, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004.

The audited financial statements at December 31, 2003, which are included in the Company's Form 10-K, should be read in conjunction with these condensed consolidated financial statements.

Unless otherwise indicated or the context requires, all references in this Form 10-Q to the Company refers to Metropolitan Health Networks, Inc. and our consolidated subsidiaries.

SEGMENT REPORTING

The Company applies Financial Accounting Standards Boards (FASB) statement No. 131, Disclosure about Segments of an Enterprise and Related Information . The Company has considered its operations and has determined that in 2003 it operated in two segments, PSN (managed care and direct medical services) and pharmacy, and in 2004 operates only the PSN segment for purposes of presenting financial information and evaluating performance, as the pharmacy operations were sold in November 2003.

As such, the accompanying financial statements present information in a format that is consistent with the financial information used by management for internal use.

INCOME TAXES

The Company accounts for income taxes according to Statement of Financial Accounting Standards No. 109, which requires a liability approach to calculating deferred income taxes. Under this method, the Company records deferred taxes based on temporary differences between the tax bases of the Company's assets and liabilities and their financial reporting bases. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized.

The effective tax rate for the three months ended March 31, 2004 differed from the federal statutory rate due principally to a decrease in the deferred tax asset valuation allowance.

REVENUES

Revenues are recorded when services are rendered. Revenues from one health maintenance organization (HMO) accounted for approximately 99% of the Company's total revenues for the quarters ended March 31, 2004 and 2003.

Contracts with the HMO in the South Florida and Daytona markets renew automatically unless cancelled by either party with 180-day notice. These contracts expired December 31, 2003, however the contracts were renewed for one

year effective January 1, 2004. The Company expects the contracts to continue for the foreseeable future.

RECLASSIFICATION

Certain amounts reported in the comparative financial statements have been reclassified to conform to the presentation for the period ended March 31, 2004.

F-5

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

ACCOUNTS RECEIVABLE

Accounts receivable at March 31, 2004 and December 31, 2003 were as follows:

	March 31, 2004	December 31, 2003
	<u> </u>	<u> </u>
HMO accounts receivable, net	\$ 1,859,000	\$ 1,780,000
Non-HMO accounts receivable, net	262,000	359,000
	<u> </u>	<u> </u>
Accounts receivable	<u>\$2,121,000</u>	<u>\$2,139,000</u>

In the health care environment, estimates often change as a result of one or more future confirming events. With regard to revenues, expenses and receivables arising from agreements with the HMO, the Company estimates amounts it believes will ultimately be realizable through the use of judgments and assumptions. It is possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

Direct medical costs are based in part upon estimates of claims incurred but not reported (IBNR) and estimates of retroactive adjustments or unsettled costs to be applied by the HMO. The IBNR estimates are made by the HMO utilizing actuarial methods and are continually evaluated by management of the Company, based upon its specific claims experience. The estimates of retroactive adjustments or unsettled costs to be applied by the HMO are based upon current agreements and understandings with the HMO to modify certain amounts previously charged to the Company's fund balances. Management believes its estimates of IBNR claims and estimates of retroactive adjustments are reasonable, however, it is possible the Company's estimate of these costs could change in the near term, and those changes may be material.

From time to time the Company is charged for certain medical expenses which, under its contracts with the HMO, the Company believes it is not liable. In connection therewith, the Company was contesting certain costs aggregating approximately \$4.2 million at March 31, 2004. Management's estimate of recovery on these contestations is determined based upon its judgment and its consideration of several factors including the nature of the contestations, historical recovery rates and other qualitative factors. Accordingly, accounts receivable due from the HMO include approximately \$835,000, which represents estimated recovery of contestations outstanding at March 31, 2004. It is possible the Company's estimate of these recoveries could change in the near term, and those changes may be material.

Non-HMO accounts receivable, aggregating approximately \$2.9 million at March 31, 2004 relate principally to medical services provided on a fee for service basis, and are reduced by amounts estimated to be uncollectible (approximately \$2.6 million). Management's estimate of uncollectible amounts is based upon its analysis of historical collections and other qualitative factors, however it is possible the Company's estimate of uncollectible amounts could change in the near term, and those changes may be material. Non-HMO accounts receivable included approximately \$2.0 million from operations discontinued in prior years, which, although the Company continues to pursue collection, is fully reserved.

F-6

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Non-HMO accounts receivable are typically uncollateralized customer obligations due under normal trade terms requiring payment within 30-90 days from the invoice date. The Company does not charge late fees or penalties on delinquent invoices, however it continually evaluates the need for a valuation allowance. The allowance reflects management's best estimate of the amounts that will not be collected. Management reviews all non-current accounts receivable balances on an ongoing basis and, based on its assessment of current creditworthiness, estimates the portion, if any, that will not be collected. It is possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

NET INCOME PER SHARE

The Company applies Statement of Financial Accounting Standards No. 128, Earnings Per Share (FAS 128) which requires dual presentation of net income per share; Basic and Diluted. Basic earnings per share is computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares outstanding during the period adjusted for incremental shares attributed to outstanding options and warrants, convertible debt and preferred stock to purchase or convert into shares of common stock.

	For the three months ended March 31,	
	2004	2003
	<hr/>	<hr/>
Net Income from continuing operations	\$ 1,490,767	\$ 964,692
Less: Preferred stock dividend	(12,500)	(12,500)
	<hr/>	<hr/>
	1,478,267	952,192
Loss from discontinued operations	(45,958)	(248,995)
	<hr/>	<hr/>
Income available to common shareholders	\$ 1,432,309	\$ 703,197
	<hr/>	<hr/>
Denominator:		
Weighted average common shares outstanding	41,722,527	32,273,745
	<hr/>	<hr/>
Basic earnings per common share	\$ 0.03	\$ 0.02
	<hr/>	<hr/>
Net Income	\$ 1,444,809	\$ 715,697
Interest on convertible securities	2,427	103,920
	<hr/>	<hr/>

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

	\$ 1,447,236	\$ 819,617
	<u> </u>	<u> </u>
Denominator:		
Weighted average common shares outstanding	41,722,527	32,273,745
Common share equivalents of outstanding stock:		
Convertible preferred	1,341,730	4,437,567
Convertible debt	366,323	6,765,116
Options	2,008,794	
Warrants	283,840	
	<u> </u>	<u> </u>
Weighted average common shares outstanding	45,273,214	43,476,428
	<u> </u>	<u> </u>
Diluted earnings per common share	\$ 0.03	\$ 0.02
	<u> </u>	<u> </u>

STOCK COMPENSATION

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure-an amendment of FASB Statement No. 123. This statement provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation.

F-7

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

SFAS No. 148 amends the disclosure requirements of SFAS 123 to require disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method on reported results.

The Company adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation, (SFAS 123). The Company has elected to continue using Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees in accounting for employee stock options.

Accordingly, compensation expense for options granted to employees is recorded to the extent the market value of the underlying stock exceeds the exercise price at the date of grant. For the three months ended March 31, 2004 and 2003 no compensation was recorded. If compensation cost had been determined based on the fair value at the grant date for awards in the three months ended March 31, 2004 and 2003, consistent with the provisions of SFAS 123, the Company's net income and income per share would have been reduced to the pro-forma amounts indicated below:

	For the three months ended	
	March 31,	
	2004	2003
	<u> </u>	<u> </u>
Net Income	\$ 1,444,809	\$ 715,697
Less: Total stock-based employee compensation expense determined using the fair value method, net of related tax	<u>17,102</u>	<u>24,149</u>
Adjusted net income	<u>1,427,707</u>	<u>691,548</u>
Earnings per share:		
Basic, as reported	<u>\$ 0.03</u>	<u>\$ 0.02</u>
Basic, pro forma	<u>\$ 0.03</u>	<u>\$ 0.02</u>
Diluted, as reported	<u>\$ 0.03</u>	<u>\$ 0.02</u>
Diluted, pro forma	<u>\$ 0.03</u>	<u>\$ 0.02</u>

NEW ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 143 which requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred and a corresponding increase in the carrying amount of the related long-lived asset. Subsequently, the asset retirement cost should be allocated to expense using a systematic and rational method over its useful life. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. Adoption of SFAS No. 143 did not have a material impact on the Company s financial statements.

In April 2003, the FASB issued SFAS No. 149, which amends SFAS 133, Accounting for Derivative Instruments and Hedging Activities . The primary focus of this Statement is to amend and clarify financial accounting and reporting for derivative instruments. This Statement is effective for contracts entered into or modified after June 30, 2003. Adoption of SFAS No. 149 did not have a material impact on the Company s financial statements.

F-8

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)**

In May 2003, the FASB issued SFAS No. 150, Accounting For Certain Financial Instruments with Characteristics of both Liabilities and Equity . SFAS No. 150 changes the accounting for certain financial instruments with characteristics of both liabilities and equity that, under previous pronouncements, issuers could account for as equity. The new accounting guidance contained in SFAS No. 150 requires that those instruments be classified as liabilities in the balance sheet. SFAS No. 150 affects the issuer's accounting for three types of freestanding financial instruments. One type is mandatory redeemable shares, which the issuing company is obligated to buy back in exchange for cash or other assets. A second type includes put options and forward purchase contracts, which involves instruments that do or may require the issuer to buy back some of its shares in exchange for cash or other assets. The third type of instruments that are liabilities under this Statement is obligations that can be settled with shares, the monetary value of which is fixed, tied solely or predominantly to a variable such as a market index, or varies inversely with the value of the issuer's shares. SFAS No. 150 does not apply to features embedded in a financial instrument that is not a derivative in its entirety. Most of the provisions of SFAS No. 150 are consistent with the existing definition of liabilities in FASB Concepts Statement No. 6, Elements of Financial Statements . The remaining provisions of this Statement are consistent with the FASB's proposal to revise that definition to encompass certain obligations that a reporting entity can or must settle by issuing its own shares. This Statement shall be effective for financial instruments entered into or modified after May 31, 2003 and otherwise shall be effective at the beginning of the first interim period beginning after June 15, 2003, except for mandatory redeemable financial instruments of a non-public entity, as to which the effective date is for fiscal periods beginning after December 15, 2003. Adoption of SFAS No. 150 did not have a material impact on the Company's financial statements.

NOTE 2. DEBT

During the first quarter of 2004, the Company repaid \$709,000 of long-term debt that was due during the quarter and restructured a \$1.2 million note due May 2004. The new terms provide for payment over twenty-four months beginning in June 2004, with interest at 12%. 100,000 shares of common stock were issued in conjunction with the restructuring.

NOTE 3. STOCKHOLDERS' EQUITY

During the first three months of 2004, the Company issued 290,980 shares of common stock for the exercise of stock options, board compensation and loan fees. In addition, the Company issued 1,869,070 shares of common stock for the conversion of \$1,015,000 of long-term debt and 5,005,000 shares, at \$0.60 per share, in a private placement related to its IRS settlement.

NOTE 4. COMMITMENTS AND CONTINGENCIES

LITIGATION

The Company is a party to certain claims arising in the ordinary course of business. Management believes that the outcome of these matters will not have a material adverse effect on the financial position or the results of operations of the Company.

PAYROLL TAXES PAYABLE

In 2000, the Company negotiated an installment plan with the Internal Revenue Service (IRS) related to unpaid payroll tax liabilities, including accrued interest and penalties. Under the plan the Company was required to make monthly installments of \$100,000 on the amount in arrears. The agreement expired and the full amount was deemed

due upon demand.

In February 2004, the Company was successful in negotiating a settlement with the IRS on its outstanding payroll tax liabilities for an amount totaling approximately \$3.3 to \$3.4 million. To date, \$3.2 million of this settlement has been paid with the balance to be paid once the IRS has determined the final settlement amount

F-9

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 5. BUSINESS SEGMENT INFORMATION

The Company operates in one segment during 2004 for purposes of presenting financial information and evaluating performance, the PSN (managed care and direct medical services) division. During 2003, the Company also operated a second segment, a pharmacy. The Company allocated corporate overhead to the pharmacy during the period it was operational. However, the overhead allocation is not included in the loss from operations of the discontinued business segments shown in the condensed consolidated statements of operations. The PSN segment also includes all costs related to the Company's consideration and development of an HMO concept.

THREE MONTHS ENDED MARCH 31, 2004	PSN	Pharmacy	Total
Revenues from external customers	\$38,543,000	\$	\$38,543,000
Segment gain (loss) before allocated overhead	2,647,000	(46,000)	2,601,000
Allocated corporate overhead	1,156,000		1,156,000
Segment gain (loss) after allocated overhead	1,491,000	(46,000)	1,445,000
THREE MONTHS ENDED MARCH 31, 2003	PSN	Pharmacy	Total
Revenues from external customers	\$36,877,000	\$	\$36,877,000
Intersegment revenues from discontinued business segments		317,000	317,000
Revenues from discontinued business segments		3,906,000	3,906,000
Segment gain (loss) before allocated overhead	2,311,000	(249,000)	2,062,000
Allocated corporate overhead	825,000	487,000	1,312,000
Segment gain (loss) after allocated overhead	1,486,000	(770,000)	716,000

F-10

Table of Contents

INDEPENDENT AUDITORS REPORT

To the Board of Directors and Stockholders
Metropolitan Health Networks, Inc. and Subsidiaries
West Palm Beach, Florida

We have audited the accompanying consolidated balance sheets of Metropolitan Health Networks, Inc. and Subsidiaries as of December 31, 2003 and 2002, and the related consolidated statements of operations, changes in stockholders equity (deficiency in assets), and cash flows for each of the three years in the period ended December 31, 2003. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Metropolitan Health Networks, Inc. and Subsidiaries as of December 31, 2003 and 2002, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2003, in conformity with accounting principles generally accepted in the United States of America.

KAUFMAN, ROSSIN & CO., P.A.

Miami, Florida

February 27, 2004, except for Notes 2, 7 and 14, as to which the date is March 22, 2004

F-11

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS**

	December 31,	
	2003	2002
ASSETS		
CURRENT ASSETS		
Cash and equivalents	\$ 2,176,204	\$ 399,614
Accounts receivable, net of allowance of \$2,539,231 and \$4,647,663, Respectively	2,138,690	1,651,340
Inventory	304,248	158,714
Other current assets	833,112	443,896
Assets held for sale		3,303,599
TOTAL CURRENT ASSETS	5,452,254	5,957,163
CERTIFICATES OF DEPOSIT restricted	1,000,000	850,000
CERTIFICATES OF DEPOSIT RECEIVABLE restricted		150,000
PROPERTY AND EQUIPMENT, net of accumulated depreciation and amortization of \$2,363,354 and \$1,998,311, respectively	659,682	883,763
GOODWILL, net of accumulated amortization of \$752,691	1,992,133	1,992,133
OTHER ASSETS	119,660	325,852
TOTAL ASSETS	\$ 9,223,729	\$ 10,158,911
LIABILITIES AND DEFICIENCY IN ASSETS		
CURRENT LIABILITIES		
Advances from HMO	\$ 164,536	\$ 1,666,953
Accounts payable	1,756,347	3,774,778
Accrued expenses	1,413,195	1,420,977
Current maturities of capital lease obligations	104,315	126,220
Current maturities of long-term debt	975,169	2,234,521
Payroll taxes payable	3,408,736	3,805,598
Liabilities related to assets held for sale		755,528
TOTAL CURRENT LIABILITIES	7,822,298	13,784,575
CAPITAL LEASE OBLIGATIONS	3,092	122,416
LONG-TERM DEBT	1,901,000	3,120,213
TOTAL LIABILITIES	9,726,390	17,027,204

COMMITMENTS AND CONTINGENCIES

DEFICIENCY IN ASSETS

Preferred stock, par value \$.001 per share; stated value \$100 per share; 10,000,000 shares authorized; 5,000 issued and outstanding	500,000	500,000
Common stock, par value \$.001 per share; 80,000,000 shares authorized; 38,527,699 and 31,376,822 issued and outstanding, respectively	38,527	31,376
Additional paid-in capital	31,343,887	29,660,886
Accumulated deficit	(32,238,333)	(36,640,086)
Common stock issued for services to be rendered	(146,742)	(420,469)
	<u> </u>	<u> </u>
 TOTAL DEFICIENCY IN ASSETS	 (502,661)	 (6,868,293)
	<u> </u>	<u> </u>
 TOTAL LIABILITIES AND DEFICIENCY IN ASSETS	 \$ 9,223,729	 \$ 10,158,911
	<u> </u>	<u> </u>

See accompanying notes to consolidated financial statements.

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

	For the years ended December 31,		
	2003	2002	2001
REVENUES	\$143,874,488	\$140,063,566	\$128,186,307
EXPENSES			
Direct medical costs	121,010,410	133,587,130	114,594,876
Payroll, payroll taxes and benefits	7,846,785	7,698,593	6,076,115
Medical supplies	2,127,009	1,913,446	62,717
Depreciation and amortization	654,942	946,325	845,798
Bad debt expense	100,000	250,000	288,000
Rent and leases	1,016,152	854,349	756,906
Consulting expense	1,351,446	2,663,362	1,081,800
General and administrative	2,556,676	3,048,538	2,278,463
TOTAL EXPENSES	136,663,420	150,961,743	125,984,675
INCOME/(LOSS) BEFORE OTHER INCOME (EXPENSE)	7,211,068	(10,898,177)	2,201,632
OTHER INCOME (EXPENSE):			
Gain (loss) on settlements of litigation	(105,000)	(65,389)	177,000
Write down of accounts receivable from closed practices		(520,000)	(775,000)
Interest and penalty expense	(1,322,878)	(2,443,851)	(649,091)
Other income	78,113	61,617	43,449
TOTAL OTHER INCOME (EXPENSE)	(1,349,765)	(2,967,623)	(1,203,642)
INCOME/(LOSS) FROM CONTINUING OPERATIONS	5,861,303	(13,865,800)	997,990
DISCONTINUED OPERATIONS:			
Gain (Loss) on disposal of discontinued business segments	289,605	(833,657)	
Loss from operations of discontinued business segments	(1,749,155)	(2,381,430)	(1,303,404)

LOSS FROM DISCONTINUED OPERATIONS	<u>(1,459,550)</u>	<u>(3,215,087)</u>	<u>(1,303,404)</u>
NET INCOME (LOSS) BEFORE INCOME TAXES	4,401,753	(17,080,887)	(305,414)
INCOME TAX EXPENSE			<u>(63,827)</u>
NET INCOME/(LOSS)	<u>\$ 4,401,753</u>	<u>\$ (17,080,887)</u>	<u>\$ (369,241)</u>
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	<u>34,750,173</u>	<u>30,374,669</u>	<u>25,859,411</u>
INCOME (LOSS) FROM CONTINUING OPERATIONS:			
Basic	<u>\$ 0.17</u>	<u>\$ (0.46)</u>	<u>\$ 0.03</u>
Diluted	<u>\$ 0.13</u>	<u>\$ (0.46)</u>	<u>\$ 0.03</u>
LOSS FROM DISCONTINUED OPERATIONS:			
Basic	<u>\$ (0.04)</u>	<u>\$ (0.10)</u>	<u>\$ (0.05)</u>
Diluted	<u>\$ (0.03)</u>	<u>\$ (0.10)</u>	<u>\$ (0.05)</u>
NET EARNINGS (LOSS) PER SHARE:			
Basic	<u>\$ 0.13</u>	<u>\$ (0.56)</u>	<u>\$ (0.02)</u>
Diluted	<u>\$ 0.10</u>	<u>\$ (0.56)</u>	<u>\$ (0.02)</u>

See accompanying notes to consolidated financial statements

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY
(DEFICIENCY IN ASSETS)
FOR THE YEARS ENDED DECEMBER 31, 2003, 2002 AND 2001

	Preferred Shares	Preferred Stock	Common Stock Shares	Common Stock	Additional Paid-in Capital	Prepaid Expenses	Accumulated Deficit	Total
BALANCES DECEMBER 31, 2000	5,000	\$500,000	21,717,233	\$21,717	\$18,936,714	\$ (33,258)	\$(19,189,958)	\$ 235,215
Shares issued in connection with private placement, net			3,312,788	3,313	5,027,986			5,031,299
Shares issued upon conversion of convertible debt			826,298	826	799,175			800,001
Shares issued for consulting services and compensation			25,000	25	15,863			15,888
Shares issued for prepaid consulting agreement, net of amortization expense			462,500	463	290,252	(278,174)		12,541
Exercise of options and warrants			685,516	686	452,202			452,888
Shares issued for directors fees			63,376	63	81,436			81,499
Shares issued for interest expense and late fees			139,443	139	61,552			61,691
Shares issued in connection with line of credit			57,767	58	73,919			73,977
Shares issued in settlement			189,166	189	102,579			102,768

of payables								
Issuance of options for services, net of amortization expense					203,227	(5,932)		197,295
Net loss							(369,241)	(369,241)
<hr/>								
BALANCES DECEMBER 31, 2001	5,000	\$500,000	27,479,087	\$27,479	\$26,044,905	\$(317,364)	\$(19,559,199)	\$ 6,695,821
Shares issued in connection with private placement, net			200,000	200	199,800			200,000
Shares issued upon conversion of convertible debt			1,251,778	1,252	1,010,371			1,011,623
Shares issued for consulting services and compensation			1,070,000	1,070	223,897	(221,100)		3,867
Shares issued for commissions, net			265,500	266	66,801	(50,000)		17,067
Exercise of options and warrants			67		67			67
Shares issued for directors fees			57,274	57	69,943			70,000
Shares issued for interest expense and late fees			263,000	263	132,130	(57,778)		74,615
Shares issued in connection with equity line, net			38,475	38	35,667			35,705
Shares issued in settlement of payables			801,641	801	271,650			272,451
Shares cancelled in connection with previous			(50,000)	(50)	(66,617)			(66,667)

acquisition								
Cancellation of warrants					(72,000)			(72,000)
Issuance of options for services, net					523,900	(189,000)		334,900
Imputed interest on beneficial conversion feature					1,220,372			1,220,372
Amortization of prepaid expenses						414,773		414,773
Net loss							(17,080,887)	(17,080,887)
BALANCES								
DECEMBER 31, 2002	5,000	\$ 500,000	31,376,822	\$ 31,376	\$ 29,660,886	\$(420,469)	\$(36,640,086)	\$ (6,868,293)
Shares issued upon conversion of convertible debt			3,670,214	3,670	1,093,834			1,097,504
Cancellation of shares issued for consulting services			(480,000)	(480)	(63,521)	64,001		
Shares issued for compensation			100,000	100	18,900			19,000
Exercise of options and warrants			110,000	110	34,390			34,500
Shares issued for directors fees			329,760	330	57,170			57,500
Shares issued for interest expense, late fees and loan extension			2,865,272	2,865	386,195	(120,000)		269,060
Shares issued in settlement of payables			555,631	556	156,033			156,589
Amortization of prepaid expenses						329,726		329,726
Net income							4,401,753	4,401,753

BALANCES
DECEMBER
31, 2003

5,000	\$ 500,000	38,527,699	\$ 38,527	\$ 31,343,887	\$(146,742)	\$(32,238,333)	\$ (502,661)
-------	------------	------------	-----------	---------------	-------------	----------------	--------------

See accompanying notes to consolidated financial statements

F-14

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the years ended December 31,		
	2003	2002	2001
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income/(loss)	\$ 4,401,753	\$(17,080,887)	\$ (369,241)
Adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities:			
Unfavorable (favorable) resolution of unsettled medical costs		6,598,563	(1,879,000)
Provision and medical cost adjustments related to HMO receivables			
Gain on settlements of litigation			(177,000)
Gain on sale of business segment	(289,605)		
Write-down of accounts receivable from closed practices		520,000	775,000
Loss on disposal of business segment		833,657	
Write-down of goodwill from closed practices			54,161
Depreciation and amortization	529,228	946,325	845,798
Provision for bad debts and direct write-downs	100,000	550,000	288,000
Amortization of discount on notes payable	201,092	103,798	36,206
Interest imputed on beneficial conversion feature		1,220,372	
Stock issued for interest and late fees	80,000		61,691
Stock issued in connection with settlements			102,768
Stock issued for compensation and services	288,598	86,800	97,362
Warrants and options granted in lieu of compensation		414,773	81,800
Amortization of securities issued for professional services	329,726	313,527	128,036
Changes in assets and liabilities:			
Accounts receivable, net	(587,350)	756,604	(2,450,492)
Inventory	(145,534)	(158,714)	
Other current assets	(389,216)	(66,508)	(232,900)
Net change in operating assets held for sale	(262,324)	(2,309,552)	(238,519)
Other assets	42,008	(766,166)	(49,995)
Due to related parties			(105,800)
Accounts payable and accrued expenses	(1,780,119)	2,829,581	219,908
Payroll taxes payable	(396,862)	1,235,205	
Unearned revenue			(906,944)

Total adjustments	<u>(2,280,358)</u>	<u>13,108,265</u>	<u>(3,349,920)</u>
Net cash provided by/(used in) operating activities	<u>2,121,395</u>	<u>(3,972,622)</u>	<u>(3,719,161)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:			
Proceeds from sale of pharmacy	3,100,000		
Purchase of restricted certificates of deposit	(150,000)	(850,000)	
Capital expenditures	<u>(140,962)</u>	<u>(194,674)</u>	<u>(92,882)</u>
Net cash provided by/(used in) investing activities	<u>2,809,038</u>	<u>(1,044,674)</u>	<u>(92,882)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:			
Borrowings on notes payable	637,137	5,682,315	733,587
Repayments on notes payable	(2,181,834)	(1,359,326)	(434,113)
Repayments on capital lease obligations	(141,229)	(102,894)	(52,049)
Proceeds from exercise of stock options and warrants	34,500		452,888
Proceeds from issuance of warrants		353,075	
Net proceeds from issuance of common stock		235,772	5,105,905
Advances from (repayments to) HMO	<u>(1,502,417)</u>	<u>214,000</u>	<u>(1,644,931)</u>
Net cash (used in)/provided by financing activities	<u>(3,153,843)</u>	<u>5,022,942</u>	<u>4,161,287</u>
NET INCREASE IN CASH AND EQUIVALENTS			
CASH AND EQUIVALENTS BEGINNING	<u>399,614</u>	<u>393,968</u>	<u>44,724</u>
CASH AND EQUIVALENTS ENDING	<u>\$ 2,176,204</u>	<u>\$ 399,614</u>	<u>\$ 393,968</u>

See accompanying notes to consolidated financial statements

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS, CONTINUED**

	For the years ended December 31,		
	2003	2002	2001
	<u> </u>	<u> </u>	<u> </u>
Supplemental Disclosures:			
Interest Paid	\$1,383,863	\$ 980,475	\$471,130
	<u> </u>	<u> </u>	<u> </u>
Supplemental Disclosure of Non-cash Investing and Financing Activities (Note 3)			
Issuance of notes payable in connection with acquisitions	\$	\$	\$150,000
	<u> </u>	<u> </u>	<u> </u>
Fair value of assets received in connection with acquisitions	\$	\$	\$ 78,608
	<u> </u>	<u> </u>	<u> </u>
Fair value of liabilities assumed in connection with acquisitions	\$	\$	\$507,462
	<u> </u>	<u> </u>	<u> </u>
Capital lease obligations incurred on purchases of equipment	\$	\$ 45,009	\$277,074
	<u> </u>	<u> </u>	<u> </u>
Purchase price in excess of net assets acquired	\$	\$	\$158,853
	<u> </u>	<u> </u>	<u> </u>
Conversion of debt into common stock	\$1,083,465	\$1,342,343	\$800,001
	<u> </u>	<u> </u>	<u> </u>
Commitments to purchase restricted certificates of deposit	\$	\$ 150,000	\$
	<u> </u>	<u> </u>	<u> </u>
Common stock issued for extension and interest fees on loans payable	\$ 75,000	\$	\$
	<u> </u>	<u> </u>	<u> </u>
Common stock issued in connection with settlements	\$ 147,589	\$	\$
	<u> </u>	<u> </u>	<u> </u>
Conversion of accrued interest to notes payable	\$ 98,505	\$	\$
	<u> </u>	<u> </u>	<u> </u>

See accompanying notes to consolidated financial statements.

F-16

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

The consolidated financial statements include the accounts of Metropolitan Health Networks, Inc. and all subsidiaries. The consolidated group is referred to, collectively, as the Company. All significant intercompany balances and transactions have been eliminated in consolidation.

Organization and Business Activity

The Company was incorporated in January 1996, under the laws of the State of Florida for the purpose of acquiring and operating health care related businesses. The Company operates principally in South and Central Florida. The Company and certain of the wholly owned general medical practices operate under agreements with a national health maintenance organization (HMO). Commencing in 1999, the Company entered into additional agreements with the HMO in locations where it did not have owned medical practices and in connection therewith, began contracting with physicians to provide medical care to certain patients through non-owned medical practices (see accounts receivable and revenue recognition).

In October 2000, the Company acquired a clinical laboratory, which operated in South Florida. The laboratory ceased operations and was closed in July 2002. In June 2001 the Company opened a pharmacy to service its patient base in Central Florida. Commencing in the third quarter of 2001, the Company expanded its pharmacy division into New York and Maryland. In November 2003 the pharmacy operations were sold.

Segment Reporting

The Company applies Financial Accounting Standards Boards (FASB) statement No. 131, Disclosure about Segments of an Enterprise and Related Information . The Company has considered its operations and has determined that in 2001 and 2002 it operated in three segments and in 2003 it operated in two operating segments for purposes of presenting financial information and evaluating performance. As such, the accompanying financial statements present information in a format that is consistent with the financial information used by management for internal use.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. From time to time, the Company maintains cash balances with financial institutions in excess of federally insured limits.

Inventory

Inventory consists principally of prescription drugs that are stated at the lower of cost or market with costs determined by the first-in, first-out method.

Property and Equipment

Property and equipment is recorded at cost. Expenditures for major betterments and additions are charged to the asset accounts, while replacements, maintenance and repairs, which do not extend the lives of the respective assets,

are charged to expense currently.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying value of the asset.

F-17

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Depreciation and Amortization**

Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements and property under capital leases is computed on a straight-line basis over the shorter of the estimated useful lives of the assets or the term of the lease. The range of useful lives is as follows:

Machinery and equipment	5-7 years
Computer and office equipment, including items under capital lease	5-7 years
Furniture and fixtures	5-7 years
Auto equipment	5 years
Leasehold improvements	5 years

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses for the periods presented. Actual results could differ from those estimates.

In the health care environment, estimates often change as a result of one or more future confirming events. With regard to revenues, expenses and receivables arising from agreements with the HMO, the Company estimates amounts it believes will ultimately be realizable through the use of judgments and assumptions. It is reasonably possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

Direct medical costs are based in part upon estimates of claims incurred but not reported (IBNR) and estimates of retroactive adjustments or unsettled costs to be applied by the HMO. The IBNR estimates are made by the HMO utilizing actuarial methods and are continually evaluated by management of the Company based upon its specific claims experience. The estimates of retroactive adjustments or unsettled costs to be applied by the HMO are based upon current agreements and understandings with the HMO to modify certain amounts previously charged to the Company's fund balances. At December 31, 2003, approximately \$192,000 of estimated retroactive adjustments to medical costs was outstanding and included as an addition to accounts receivable. At December 31, 2002, approximately \$800,000 of estimated retroactive adjustments to medical costs was outstanding and included as an offset to advances from HMO and approximately \$500,000 of such adjustments were included in accounts receivable. Management believes its estimates of IBNR claims and estimates of retroactive adjustments are appropriate, however, it is reasonably possible the Company's estimate of these costs could change in the near term, and those changes may be material.

From time to time, the Company is charged for certain medical expenses for which, under its contract with the HMO, the Company believes it is not liable. In connection therewith, at December 31, 2003 and 2002, the Company was contesting certain costs aggregating approximately \$4.2 million and \$1.8 million, respectively. Management's estimate of recovery on these contestations is determined based upon its judgment and its consideration of several factors including the nature of the contestations, historical recovery rates and other qualitative factors. Accordingly, at December 31, 2003 and 2002 the net amount due from the HMO includes approximately \$835,000 and \$370,000,

respectively, which represents an estimated recovery of 20% of contestations outstanding at each of the two year ends. It is reasonably possible the Company's estimate of these recoveries could change in the near term, and those changes may be material.

Revenues from the HMO accounted for approximately 99% of the Company's total revenues, excluding discontinued segments, for each of the three years ended December 31, 2003 and at December 31, 2003 and 2002, the HMO represented approximately 83% and 64% of the total accounts receivable balance, respectively. Direct medical costs relating to revenues from the HMO accounted for approximately 85% of the Company's HMO revenues in 2003, 96% in 2002 and 90% in 2001. The loss of the contracts with the HMO could significantly impact the operating results of the Company.

As discussed above, the nature of the relationship with the HMO is, and has been such that certain estimates made by the Company are based upon verbal agreements with, or representations from the HMO regarding retroactive adjustments to amounts previously credited or charged to the Company's fund balance. These estimates are particularly likely to change as policy, and or personnel at the HMO changes. For the year ended December 31, 2003 there were no material changes to net income as a result of favorable or unfavorable settlements of 2002 estimates. In connection with a change in the HMO's management during 2002, deterioration in the relationship with the HMO in the fourth quarter of 2002, and other factors, during

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2002 Metropolitan recorded additional medical costs of approximately \$6.6 million related to amounts that were included in accounts receivable at December 31, 2001. Conversely, in 2001 upon favorable resolution of unsettled medical costs Metropolitan recorded a reduction to medical costs of approximately \$1.9 million. Accordingly, the 2002 gross profit and resulting net income was decreased by approximately \$6.6 million due to unfavorable settlements estimated as of December 31, 2001, and the 2001 gross profit and resulting net income was increased by approximately \$1.9 million due to favorable settlements estimated as of December 31, 2000.

Non-HMO accounts receivable, aggregating approximately \$2.9 million and \$5.2 million at December 31, 2003 and 2002, respectively, relate principally to medical services provided on a fee for service basis, and are reduced by amounts estimated to be uncollectible (approximately \$2.5 million and \$4.6 million at December 31, 2003 and 2002, respectively). Management's estimate of uncollectible amounts is based upon its analysis of historical collections and other qualitative factors, however it is reasonable possible the company's estimate of uncollectible amounts could change in the near term, and those changes may be material.

Fair Value of Financial Instruments

Statement of Financial Accounting Standards No. 107, Disclosures about Fair Value of Financial Instruments requires that the Company disclose estimated fair values for its financial instruments. The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instruments disclosed herein:

Cash and Certificates of Deposits - The carrying amount approximates fair value because of the short nature of those instruments.

Line of Credit Facilities, Capital Lease Obligations, Long-Term Debt - The fair value of line of credit facilities, capital lease obligations and long-term debt are estimated using discounted cash flows analyses based on the Company's incremental borrowing rates for similar types of borrowing arrangements. At December 31, 2003, the fair values approximate the carrying values.

Net Income (Loss) Per Share

The following table sets forth the computations of basic earnings per share and diluted earnings per share:

	For the years ended December 31,		
	2003	2002	2001
Net Income/(Loss) from continuing operations	\$ 5,861,303	\$(13,865,800)	\$ 934,163
Less: Preferred stock dividends	(50,000)	(50,000)	(50,000)
	<u>5,811,303</u>	<u>(13,915,800)</u>	<u>884,163</u>
Loss from discontinued operations	(1,459,550)	(3,215,087)	(1,303,404)
	<u>\$ 4,351,753</u>	<u>\$(17,130,887)</u>	<u>\$ (419,241)</u>

Income/(Loss) available to common shareholders	<u> </u>	<u> </u>	<u> </u>
Denominator:			
Weighted average common shares outstanding	<u>34,750,173</u>	<u>30,374,669</u>	<u>25,859,411</u>
Basic earnings/(loss) per common share	<u>\$ 0.13</u>	<u>\$ (0.56)</u>	<u>\$ (0.02)</u>
Net Income/(Loss)	\$ 4,401,753	\$(17,080,887)	\$ (369,241)
Interest on convertible securities	<u>81,379</u>	<u> </u>	<u> </u>
	<u>\$ 4,483,132</u>	<u>\$(17,080,887)</u>	<u>\$ (369,241)</u>
Denominator:			
Weighted average common shares outstanding	34,750,173	30,374,669	25,859,411
Common share equivalents of outstanding stock:			
Convertible preferred	4,901,963		
Convertible debt	<u>7,262,703</u>	<u> </u>	<u> </u>
Weighted average common shares outstanding	<u>46,914,839</u>	<u>30,374,669</u>	<u>25,859,411</u>
Diluted earnings/(loss) per common share	<u>\$ 0.10</u>	<u>\$ (0.56)</u>	<u>\$ (0.02)</u>

Table of Contents

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Securities that would potentially dilute basic earnings per share in the future were not included in the computation of diluted earnings per share because to do so would have been anti-dilutive. The anti-dilutive securities consist of the following:

During the fiscal years 2002 and 2001, the Company had 5,000 Series A preferred shares outstanding. Each share of Series A preferred stock was convertible into shares of common stock at the option of the holder at the lesser of 85% of the average closing bid price of the common stock for the ten trading days immediately preceding the conversion or \$6.00.

During the fiscal years 2003, 2002 and 2001, the Company had outstanding warrants to purchase 2,924,775, 3,324,775 and 1,844,150 shares of common stock, respectively. The exercise prices of the warrants range from \$0.32 to \$4.00 in 2003 and \$0.32 to \$6.00 in 2002 and 2001.

During the fiscal years 2003, 2002 and 2001, the Company had outstanding options to purchase 7,328,467, 5,205,717 and 5,736,250 shares of common stock, respectively. The weighted average exercise price of the options was \$0.94 in 2003, \$1.46 in 2002 and \$1.81 in 2001.

For the fiscal year 2003, the Company had convertible debt in the amount of \$67,000, which could have been converted into the common stock of the Company at \$2.50 per share.

For the fiscal year 2002, the Company had convertible debt in the amount of \$2,997,107, which could have been converted into the common stock of the Company at a range of 75% of market value at the date of conversion to \$2.50 per share.

For the fiscal year 2001, the Company had convertible debt in the amount of \$774,182, which could have been converted into the common stock of the Company at prices ranging from \$0.74 to \$2.50 per share.

Accounts Receivable and Revenue Recognition

The Company recognizes revenues, net of contractual allowances, as medical services are provided to patients. These services are typically billed to patients, Medicare, Medicaid, health maintenance organizations and insurance companies. The Company provides an allowance for uncollectible amounts and for contractual adjustments relating to the difference between standard charges and agreed upon rates paid by certain third party payers.

The Company is a party to certain managed care contracts and provides medical care to its patients through owned and non-owned medical practices. Accordingly, revenues under these contracts are reported as Provider Service Network (PSN) revenues, and the cost of provider services under these contracts are not included as a deduction to net revenues of the Company, but are reported as an operating expense. In connection with its PSN operations, the Company is exposed to losses to the extent of its share (100% for Medicare Part B, 100% for Medicare Part A in its Daytona market and 50% for Medicare Part A in South Florida) of deficits, if any, on its owned and non-owned managed medical practices.

Advances from HMO

Advances represent loans from the HMO that are due on demand. These amounts are expected to be repaid via offsets to future revenues earned from the HMO.

Goodwill

In connection with its acquisitions of physician and ancillary practices, the Company has recorded goodwill of \$1,992,133 for each of the two years ended December 31, 2003, which is the excess of the purchase price over the fair value of the net assets acquired. The goodwill is attributable to the general reputation of these businesses in the communities they serve, the collective experience of the management and other employees and relationships between the physicians and their patients. The Company has reviewed the useful lives of its identifiable intangible assets and determined that the original estimated lives remain appropriate. Effective January 1, 2002 the Company, through the use of an outside business valuation expert completed a transitional goodwill impairment test and determined that the Company did not have a transitional impairment of goodwill. Subsequent to that analysis, during the quarter ended September 30, 2002, the Company disposed of a segment of its business and charged off net goodwill of approximately \$986,000. The Company has performed its annual impairment tests relating to retained business segments effective

F-20

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

January 1, 2003 and has determined that no impairment exists.

The changes in the carrying amount of goodwill for the years ended December 31, 2003 and 2002 are as follows:

	2003	2002
	<hr/>	<hr/>
Balance as of January 1	\$1,992,133	\$2,977,874
Goodwill written off related to disposal of business segment		(985,741)
	<hr/>	<hr/>
Balance as of December 31, 2003	\$1,992,133	\$1,992,133
	<hr/>	<hr/>

As required by SFAS 142, Goodwill and Other Intangible Assets, the Company has not amortized goodwill associated with acquisitions completed after June 30, 2001, or any period presented and ceased amortization of goodwill associated with acquisitions completed prior to July 1, 2001, effective January 1, 2002. Prior to January 1, 2002, the Company amortized goodwill associated with the pre-July 1, 2001 acquisitions over ten years using the straight-line method. A reconciliation of reported net income (loss) adjusted to reflect the adoption of SFAS No. 142 is provided below:

	Year Ended December 31, 2001
	<hr/>
Reported net income (loss)	\$(369,241)
Add-back goodwill amortization, net of tax	264,338
	<hr/>
Adjusted net income (loss)	\$(104,903)
	<hr/>
Reported basic net income per share	\$ (0.02)
Add-back goodwill amortization	0.01
	<hr/>
Adjusted basic net income (loss) per share	\$ (0.01)
	<hr/>
Reported diluted net income (loss) per share	\$ (0.02)
Add-back goodwill amortization	0.01
	<hr/>

Adjusted diluted net income (loss) per share \$ (0.01)

Income Taxes

The Company accounts for income taxes according to Statement of Financial Accounting Standards No. 109, which requires a liability approach to calculating deferred income taxes. Under this method, the Company records deferred taxes based on temporary differences between the tax bases of the Company's assets and liabilities and their financial reporting bases. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized.

New Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 143 which requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred and a corresponding increase in the carrying amount of the related long-lived asset. Subsequently, the asset retirement cost should be allocated to expense using a systematic and rational method over its useful life. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. Adoption of SFAS No. 143 did not have a material impact on the Company's financial statements.

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. This statement addresses accounting and reporting for costs associated with exit or disposal activities and nullifies emerging issues Task Force Issue No. 94-3. The statement is effective for exit or disposal costs initiated after December 31, 2002, with early application encouraged. The Company adopted SFAS No. 146 effective January 1, 2003, which did not have a material impact on the Company's financial statements.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure-an amendment of FASB Statement No. 123. This statement provides alternative methods of transition for a

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

voluntary change to the fair value based method of accounting for stock-based employee compensation. SFAS No. 148 amends the disclosure requirements of SFAS 123 to require disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method on reported results.

The Company adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation, (SFAS 123). The Company has elected to continue using Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees in accounting for employee stock options.

Accordingly, compensation expense for options granted to employees is recorded to the extent the market value of the underlying stock exceeds the exercise price at the date of grant. For the years ended December 31, 2003, 2002 and 2001 no compensation was recorded. If compensation cost had been determined based on the fair value at the grant date for awards in the years ended December 31, 2003, 2002 and 2001, consistent with the provisions of SFAS 123, the Company's net loss and loss per share would have been reduced to the pro-forma amounts indicated below:

	Year Ended December 31		
	2003	2002	2001
	<u> </u>	<u> </u>	<u> </u>
Net Income/(Loss)	\$4,401,753	\$(17,080,887)	\$ (369,241)
Less: Total stock-based employee compensation expense determined using the fair value method, net of related tax effects	<u>(543,283)</u>	<u> </u>	<u>(769,544)</u>
Adjusted net income/(loss)	<u>3,858,470</u>	<u>\$(17,080,887)</u>	<u>(1,138,785)</u>
Earnings per share:			
Basic, as reported	<u>\$ 0.13</u>	<u>\$ (0.56)</u>	<u>\$ (0.02)</u>
Basic, pro forma	<u>\$ 0.11</u>	<u>\$ (0.56)</u>	<u>\$ (0.05)</u>
Diluted, as reported	<u>\$ 0.10</u>	<u>\$ (0.56)</u>	<u>\$ (0.02)</u>
Diluted, pro forma	<u>\$ 0.08</u>	<u>\$ (0.56)</u>	<u>\$ (0.05)</u>

On January 17, 2003, FIN 46, Consolidation of Variable Interest Entities, an interpretation of ARB 51, was issued. The primary objective of FIN 46 is to provide guidance on the identification and consolidation of variable interest entities, or VIEs, which are entities for which control is achieved through means other than through voting rights. The provision of FIN 46 was required to be adopted by the Company in fiscal 2003. The Company adopted FIN 46 effective January 1, 2003, with no material impact on its financial position, results of operations or cash flows.

In April 2003, the FASB issued SFAS No. 149, which amends SFAS 133, Accounting for Derivative Instruments and Hedging Activities. The primary focus of this Statement is to amend and clarify financial accounting and reporting for derivative instruments. This Statement is effective for contracts entered into or modified after June 30, 2003. Adoption of SFAS No. 149 did not have a material impact on the Company's financial statements.

In May 2003, the FASB issued SFAS No. 150, Accounting For Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS No. 150 changes the accounting for certain financial instruments with characteristics of both liabilities and equity that, under previous pronouncements, issuers could account for as equity. The new accounting guidance contained in SFAS No. 150 requires that those instruments be classified as liabilities in the balance sheet. SFAS No. 150 affects the issuer's accounting for three types of freestanding financial instruments. One type is mandatory redeemable shares, which the issuing company is obligated to buy back in exchange for cash or other assets. A second type includes put options and forward purchase contracts, which involves instruments that do or may require the issuer to buy back some of its shares in exchange for cash or other assets. The third type of instruments that are liabilities under this Statement is obligations that can be settled with shares, the monetary value of which is fixed, tied solely or predominantly to a variable such as a market index, or varies inversely with the value of the issuer's shares. SFAS No. 150 does not apply to features embedded in a financial instrument that is not a derivative in its entirety. Most of the provisions of SFAS No. 150 are consistent with the existing definition of liabilities in FASB Concepts Statement No. 6, Elements of Financial

Table of Contents

**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Statements . The remaining provisions of this Statement are consistent with the FASB's proposal to revise that definition to encompass certain obligations that a reporting entity can or must settle by issuing its own shares. This Statement shall be effective for financial instruments entered into or modified after May 31, 2003 and otherwise shall be effective at the beginning of the first interim period beginning after June 15, 2003, except for mandatory redeemable financial instruments of a non-public entity, as to which the effective date is for fiscal periods beginning after December 15, 2003. Adoption of SFAS No. 150 did not have a material impact on the Company's financial statements.

Reclassifications

Certain amounts in the 2002 and 2001 financial statements have been reclassified to conform to the 2003 presentation.

NOTE 2. LIQUIDITY

At December 31, 2002 the Company had a working capital deficit of \$7.8 million, and prior to that date, the Company incurred substantial negative cash flows from operations since inception. To address these issues, among other things in late 2002 Management approached the HMO, seeking to renegotiate its contract. The Company successfully completed an amendment, which, effective January 1, 2003, provided for an increase in gross revenues on a per-member per-month basis. Also, management conducted a review of each division in an effort, not only to reduce costs, but also to increase revenues or eliminate non-profitable operations.

For the year ended December 31, 2003 the Company achieved positive cash flows from operating activities of approximately \$2.1 million and improved its working capital deficit from approximately \$7.8 million at December 31, 2002 to \$2.4 million at December 31, 2003. Further significant improvements to the Company's working capital position were realized subsequent to December 31, 2003 as a consequence of certain actions by the Company; i) the Company raised approximately \$3,000,000 under a private placement of its common stock and used these funds, plus certain cash generated from operations to settle approximately \$3.4 million in past due payroll tax related liabilities, ii) the Company was able to repay approximately \$1.0 million of debt by issuing common stock, and iii) the Company has finalized an extension for payment over twenty-four months, of approximately \$1.2 million in debt due May 2004.

Notwithstanding the improved cash flows and working capital position, the Company has not demonstrated the ability to achieve income and positive cash flows for an extended period of time. Also, as the Company derives substantially all of its revenue from one HMO, and it is subject changes in the government reimbursement rates, it is at least reasonably possible the Company's liquidity may not be sufficient to sustain operations or planned growth. Although management believes the operational and cash flow improvements realized during 2003 will continue, there are no assurances this will occur into the foreseeable future.

NOTE 3. ACQUISITIONS AND DISPOSALS

In the third quarter of 2002 the Company disposed of its clinical laboratory. Accordingly, for the year ended December 31, 2002, the Company recognized an \$834,000 loss on the disposal of laboratory operations.

In November 2003, the Company sold the operations of its pharmacy division for a cash price of \$3.1 million plus the assumption of approximately \$1.1 in liabilities. Accordingly, for the year ended December 31, 2003, the Company recognized a gain of \$290,000 on the disposal of pharmacy operations.

Revenues from operations of discontinued business segments totaled \$12,906,000, \$13,761,000 and \$3,344,000 for the years ended December 31, 2003, 2002 and 2001, respectively. Losses from operations of discontinued business segments were \$1,700,000, \$2,400,000 and \$1,300,000 for the years ended December 31, 2003, 2002 and 2001, respectively.

F-23

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****NOTE 4. PROPERTY AND EQUIPMENT**

Property and equipment consisted of the following:

	December 31,	
	2003	2002
Equipment under capital lease	\$ 674,633	\$ 674,633
Machinery and medical equipment	249,881	249,881
Furniture and fixtures	382,451	339,378
Leasehold improvements	692,297	655,221
Computer and office equipment	962,394	901,581
Automobile equipment	61,380	61,380
	<hr/>	<hr/>
	3,023,036	2,882,074
Less accumulated depreciation and amortization	(2,363,354)	(1,998,311)
	<hr/>	<hr/>
	\$ 659,682	\$ 883,763
	<hr/>	<hr/>

Accumulated amortization of equipment under capital leases was \$534,000 and \$435,000 at December 31, 2003 and 2002, respectively.

Depreciation and amortization of property and equipment totaled approximately \$365,000, \$433,000 and \$453,000 for the years ended December 31, 2003, 2002 and 2001, respectively.

NOTE 5. UNEARNED REVENUE

On August 22, 2000, the Company entered into a Pharmacy Services Agreement (Pharmacy Agreement) with a medical management and software company (Pharmacy Consultant), to provide consulting, technology, and software services for the Company's start-up pharmacy operation, for an initial term of three years. In connection with this agreement, the Pharmacy Consultant paid the Company \$500,000, subject to return if the Company elects to cancel the Pharmacy Agreement under certain provisions. On October 6, 2000, the Company received an additional \$500,000 in funding from the Pharmacy Consultant in connection with a 10-year exclusive preferred provider agreement. This amount was required to be repaid, together with interest at prime plus 2%, should the Company default or elect to cancel the Agreement. Of these amounts, approximately \$132,000 was recognized as revenue during the year ended December 31, 2001.

On June 1, 2001, the Company terminated these agreements. Under the terms of the termination, the Company purchased assets totaling \$99,000 and assumed certain liabilities totaling \$78,000 of a Daytona pharmacy servicing the Company's patients. In addition, the Company agreed to retain the Pharmacy Consultant for a period of one year

for a prepaid amount of \$300,000. Total consideration paid for the net assets and the unamortized balances on the agreements was \$1,028,000, on which the Company recognized a gain in the amount of \$68,000.

NOTE 6. CAPITAL LEASE OBLIGATIONS

The Company is obligated under capital leases relating to certain of its property and equipment. Future minimum lease payments for capital lease obligations for years subsequent to December 31, 2003 are as follows:

2004	\$ 111,835
2005	5,285
	<u> </u>
	117,120
Less amount representing interest	(9,713)
	<u> </u>
	107,407
Less current maturities	(104,315)
	<u> </u>
	\$ 3,092
	<u> </u>

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****NOTE 7. LONG-TERM DEBT**

Long-term debt consisted of the following:

	December 31, 2003	2002
	<hr/>	<hr/>
Promissory Note payable to a venture capital group; unsecured, with interest payable quarterly at a rate of 12%. Principal due May 24, 2004. The note has 500,000 attached warrants to purchase common stock of the Company at \$0.68. Approximately \$254,000 of the funds received was assigned to the warrants and this amount is being amortized and charged to interest expense over two years under the interest method. After the effect of the value assigned to the warrants, the effective rate on the note was approximately 29%. In March 2004, the Company renegotiated an extension, with payments due over twenty-four months.	\$ 1,182,909	\$ 1,049,037
Convertible debentures payable to a venture capital group; unsecured, with interest payable quarterly at a rate of 6%, increasing to 13% on default. Principal due May 24, 2004. The debenture has 150,000 attached warrants to purchase common stock of the Company at \$0.68. The holder, at its discretion, may convert into shares of common stock of the Company at 75% of market value at the date of conversion. Approximately \$60,000 of the funds received was assigned to the warrants and this amount, along with a \$79,000 discount, is being amortized and charged to interest expense over two years under the interest method. After the effect of the value assigned to the warrants, the effective rate on the note is 11%. During 2003, \$865,000 of the note balance was converted into common stock of the Company. In January 2004, the balance of the note was converted into common stock.	679,906	1,477,686
Promissory note payable to an investment limited partnership; secured by common stock of the Company, with interest payable monthly at 24%. This note was repaid in full March 2004.	620,000	500,000
Convertible debentures payable to a shareholder; unsecured, with interest payable quarterly at a rate of 6%. The holder, at its discretion, may convert amount outstanding into shares of common stock of the Company at a price of \$0.43. Principal plus accrued interest due August 16, 2004. In March 2004, this note was converted into common stock of the Company.	168,000	168,000
Promissory note payable to a shareholder; unsecured, with interest payable quarterly at a rate of 12%. Principal plus accrued interest due August 16, 2004. In March 2004, this note was converted into common stock of the Company.	132,000	132,000

Promissory note payable to a shareholder of the Company, interest at 8% due and payable on March 30, 2004, or as otherwise agreed to by the parties. The payee at his discretion may convert amount outstanding on the note into shares of the common stock of the Company at \$2.50 per share. The note has 16,667 attached warrants at prices ranging from \$2.50 to \$4.00, also expiring March 30, 2004.	67,000	67,000
Note payable to HMO; interest at 5%, increased to 14% if note defaults; payable in 60 monthly installments of \$7,489 commencing May 1, 1999; collateralized by accounts receivable and property and equipment.	26,354	108,257
Convertible notes payable to an offshore fund; secured by certain assets of the Company, with interest payable quarterly at a rate of 23.75%. Interest and principal payable in monthly installments. The holder, at its discretion, may convert amount outstanding into shares of common stock of the Company at a price of \$0.43. During 2003, this note was repaid in full with approximately \$218,000 of the note having been converted into common stock of the Company.		1,081,430
Convertible notes payable to investor groups; payable on demand, with interest payable at 24%. Secured by certificates of deposit used as collateral for a letter of credit in favor of the HMO. These notes were repaid in full in 2003.		182,466
Amount payable to a pharmaceutical vendor; secured by pharmacy inventory, payable in three equal monthly installments with the last payment due March 2003, with interest at 0%. This note was repaid in full in 2003.		300,000
Notes payable to individuals with interest prepaid in the form of one share of the Company's common stock for each dollar loaned, plus 18% additional interest upon default; principal payable in 6 equal installments. The holders of these notes have the right to convert the outstanding obligation to common stock at \$1 per share at any time. This note was repaid in full in 2003.		202,991

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

	December 31,	
	2003	2002
	<u> </u>	<u> </u>
Note payable to venture capital group with interest at prime plus 5% (9.25% at December 31, 2002). Collateralized by certain accounts receivable and property and equipment. Repaid in full February 2003.		71,685
Note payable. Repaid in full in 2003.		14,182
	<u> </u>	<u> </u>
	2,876,169	5,354,734
Less current maturities, excluding amounts refinanced or expected to be refinanced with long-term debt or equity after December 31, 2003	975,169	2,234,521
	<u> </u>	<u> </u>
Long-term debt and amounts refinanced with long-term debt or equity after December 31, 2003	\$1,901,000	\$3,120,213
	<u> </u>	<u> </u>

Aggregate maturities of long-term debt for years subsequent to December 31, 2003, are as follows:

2004	\$ 975,169
Debt settled for stock in 2004	1,015,000
2005	600,000
2006	286,000
	<u> </u>
	\$2,876,169
	<u> </u>

NOTE 8. RELATED PARTY TRANSACTIONS**Due from Related Parties**

At December 31, 2002 amounts owed to the Company by officers totaled \$121,666. There were no amounts due to the Company by officers at December 31, 2003.

During the year ended December 31, 2003, the Company paid \$393,000 to a company owned by a shareholder and director for services rendered as a physician in the Company's provider network.

NOTE 9. INCOME TAXES

The components of income taxes were as follows:

	2003	December 31, 2002	2001
	<u> </u>	<u> </u>	<u> </u>
Provision (Benefit) for Income Taxes			
Current			
Federal	\$	\$	\$ 64,000
State			
Deferred			
Federal	1,236,000	(5,777,000)	389,000
State	213,000	(612,000)	66,000
Change in Valuation Allowance	(1,449,000)	6,389,000	(455,000)
	<u> </u>	<u> </u>	<u> </u>
Income Tax Expense	\$	\$	\$ 64,000
	<u> </u>	<u> </u>	<u> </u>

The effective tax rate for the year ended December 31, 2003, differed from the federal statutory rate due principally to a decrease in the deferred tax asset valuation allowance of \$1,449,000 offset by state income tax of \$159,000.

The effective tax rate for the year ended December 31, 2002, differed from the federal statutory rate due principally to an increase in the deferred tax asset valuation allowance of \$6,389,000 offset by state income tax benefits of \$612,000.

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The effective tax rate for the year ended December 31, 2001, differed from the federal statutory rate due principally to a decrease in the deferred tax asset valuation allowance of \$455,000 offset partially by alternative minimum taxes.

The Company has net operating loss carryforwards of approximately \$28,129,000, expiring in various years through 2022.

The approximate deferred tax assets and liabilities were as follows:

DEFERRED TAX ASSETS:

	As of December 31,	
	2003	2002
Allowances for doubtful accounts	\$ 956,000	\$ 1,868,000
Net operating loss carryforward	10,585,000	11,445,000
Amortization	162,000	
Depreciation	2,000	
	<hr/>	<hr/>
Total deferred tax assets	11,705,000	13,313,000

DEFERRED TAX LIABILITIES:

	As of December 31,	
	2003	2002
Cash basis subsidiaries		15,000
Amortization		90,000
Depreciation		54,000
	<hr/>	<hr/>
Total deferred tax liabilities		159,000
	<hr/>	<hr/>
Net deferred tax asset	11,705,000	13,154,000
Less valuation allowance	(11,705,000)	(13,154,000)
	<hr/>	<hr/>
	\$	\$
	<hr/>	<hr/>

NOTE 10. STOCKHOLDERS EQUITY

As of December 31, 2003, the Company has designated 10,000,000 preferred shares as Series A preferred stock, par value \$.001, of which 5,000 were issued and outstanding. Each share of Series A preferred stock has a stated value of \$100 and pays dividends equal to 10% of the stated value per annum. At December 31, 2003 and 2002, the

aggregate and per share amounts of cumulative dividend arrearages were approximately \$316,667 (\$63 per share) and \$266,667 (\$53 per share), respectively. Each share of Series A preferred stock is convertible into shares of common stock at the option of the holder at the lesser of 85% of the average closing bid price of the common stock for the ten trading days immediately preceding the conversion or \$6.00. The Company has the right to deny conversion of the Series A preferred stock, at which time the holder shall be entitled to receive and the Company shall pay additional cumulative dividends at 5% per annum, together with the initial dividend rate to equal 15% per annum. In the event of any liquidation, dissolution or winding up of the Company, holders of the Series A preferred stock shall be entitled to receive a liquidating distribution before any distribution may be made to holders of common stock of the Company.

The Company has also designated 7,000 shares of preferred stock as Series B preferred stock, with a stated value of \$1,000 per share. At December 31, 2003 and 2002, there were no shares of series B preferred stock issued and outstanding.

At December 31, 2003 and 2002, the Company had outstanding warrants to purchase 2,924,775 and 3,324,775 shares of common stock, respectively. The warrants are exercisable upon issuance with expiration dates ranging from two to five years and exercise prices ranging from \$0.32 to \$4.00 in 2003 and \$0.32 to \$6.00 in 2002.

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****NOTE 11. STOCK OPTIONS**

The Company adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation, (SFAS 123) in 1997. The Company has elected to continue using Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees in accounting for employee stock options. Accordingly, compensation expense has been recorded to the extent that the market value of the underlying stock exceeded the exercise price at the date of grant. For the years ended December 31, 2003, 2002 and 2001, compensation costs and professional services related to stock options amounted to approximately \$-0-, \$16,800 and \$81,800, respectively.

Stock option activity for the three years ended December 31 was as follows:

	Number of Options	Weighted Average Exercise Price
	<hr/>	<hr/>
Balance, December 31, 2000	5,051,447	\$ 1.88
Granted during the year	1,474,000	\$ 1.48
Exercised and returned during the year	(514,000)	\$ 0.59
Forfeited during the year	(275,197)	\$ 4.26
	<hr/>	
Balance, December 31, 2001	5,736,250	\$ 1.81
Granted during the year	200,000	\$ 0.40
Exercised and returned during the year	(67)	\$ 1.00
Forfeited during the year	(730,466)	\$ 2.11
	<hr/>	
Balance, December 31, 2002	5,205,717	\$ 1.46
Granted during the year	2,710,400	\$ 0.38
Exercised and returned during the year	(110,000)	\$ 0.31
Forfeited during the year	(477,650)	\$ 3.67
	<hr/>	
Balance, December 31, 2003	7,328,467	\$ 0.94
	<hr/>	
Exercisable, December 31, 2001	3,939,974	\$ 1.85
	<hr/>	
Exercisable, December 31, 2002	4,381,946	\$ 1.46
	<hr/>	
Exercisable, December 31, 2003	6,840,134	\$ 0.97

The following table summarizes information about stock options outstanding at December 31, 2003:

Exercise Price	Options Outstanding		Options Exercisable	
	Weighted Average Remaining Number of Options	Contractual Life (Years)	Weighted Average Remaining Number of Options	Contractual Life (Years)
\$0.250 - \$1.000	6,137,867	3.42	5,649,534	3.23
\$1.140 - \$2.000	559,000	2.26	559,000	2.26
\$2.020 - \$3.000	302,000	2.48	302,000	2.48
\$3.250 - \$5.000	132,600	2.17	132,600	2.17
\$5.500 - \$8.000	197,000	2.72	197,000	2.72
	<u>7,328,467</u>		<u>6,840,134</u>	

The weighted average fair value per option as of grant date was \$0.21 for stock options granted during the year ended December 31, 2003. The determination of the fair value of all stock options granted during the year ended December 31, 2003 was based on (i) risk-free interest rate of 2.28%, (ii) expected option lives of three years, depending on the vesting provisions of each option, (iii) expected volatility in the market price of the Company's common stock of 100%, and (iv) no expected dividends on the underlying stock.

The weighted average fair value per option as of grant date was \$0.58 for stock options granted during the year ended December 31, 2002. The determination of the fair value of all stock options granted during the year ended December 31, 2002 was based on (i) risk-free interest rate of 5.01%, (ii) expected option lives ranging from 1 to 4 years, depending on the vesting provisions of each option, (iii) expected volatility in the market price of the Company's common stock of 100%, and (iv) no expected dividends on the underlying stock.

The weighted average fair value per option as of grant date was \$0.21 for stock options granted during the year ended December 31, 2001. The determination of the fair value of all stock options granted during the year ended December 31, 2001

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

was based on (i) risk-free interest rate of 5.3%, (ii) expected option lives ranging from 1 to 7 years, depending on the vesting provisions of each option, (iii) expected volatility in the market price of the Company's common stock of 100%, and (iv) no expected dividends on the underlying stock.

NOTE 12. COMMITMENTS AND CONTINGENCIES**Leases**

The Company leases office and medical facilities under various non-cancelable operating leases. Approximate future minimum payments under these leases for the years subsequent to December 31, 2003 are as follows:

	Annual Amount	Sublease Amount	Net Minimum Payment
2004	\$ 868,000	\$ 239,000	\$ 629,000
2005	860,000	247,000	613,000
2006	699,000	195,000	504,000
2007	504,000	197,000	307,000
2008	242,000	129,000	113,000
Thereafter	592,000	534,000	58,000
	<hr/>	<hr/>	<hr/>
Total	\$3,765,000	\$1,541,000	\$2,224,000
	<hr/>	<hr/>	<hr/>

In connection with the sale of the pharmacy division, the Company has subleased pharmacy facilities to the buyer. In the event of the buyers default, the Company potentially could be responsible to fulfill these lease commitments.

Employment Contracts

The Company has employment contracts with certain executives, physicians and other clinical and administrative employees. Future annual minimum payments under these employment agreements for the years subsequent to December 31, 2003 are as follows:

2004	\$1,447,000
2005	610,000
2006	240,000
	<hr/>
	\$2,297,000
	<hr/>

Litigation

In July 2003 a pharmacy services company (the Plaintiff) filed a complaint against the Company and its pharmacy division, Metcare Rx, seeking amounts and damages of up to \$2.5 million related to the acquisition of the Maryland pharmacy operation in October 2001. On November 6, 2003 the parties reached a settlement on this complaint in the amount of \$500,000, of which the Company had previously accrued \$487,000. Pursuant to the settlement, the Company paid \$285,000 in 2003, with the balance plus accrued interest at 10% payable in monthly installments of \$35,000 until paid in full. This amount is included in accounts payable at December 31, 2003.

The Company is a party to certain other claims arising in the ordinary course of business. Management believes that the outcome of these matters will not have a material adverse effect on the financial position or the results of operations of the Company.

Investigation

In June 2003, the Company was informed that the U.S. Attorneys Office in Wilmington, Delaware was conducting an investigation of the Company. The Company fully cooperated with the U.S. Attorneys Office and on February 9, 2004 the investigation was terminated.

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Payroll Taxes Payable**

In 2000, the Company negotiated an installment plan with the Internal Revenue Service (IRS) related to unpaid payroll tax liabilities, including accrued interest and penalties. Under the plan the Company was required to make monthly installments of \$100,000 on the amount in arrears. The agreement expired and the full amount was deemed due upon demand.

In February 2004 the Company was successful in negotiating a settlement with the IRS on its outstanding payroll tax liabilities for an amount totaling approximately \$3.3 to \$3.4 million. To date, \$3.2 million of this settlement has been paid with the balance to be paid once the IRS has determined the final settlement amount.

NOTE 13. SEGMENTS

The Company operated in two segments during 2003 for purposes of presenting financial information and evaluating performance, PSN (managed care and direct medical services) and pharmacy. During 2002 and 2001, the Company also operated a third segment, a clinical laboratory.

YEAR ENDED DECEMBER 31, 2003	PSN	Pharmacy	Laboratory	Total
Revenues from external customers	\$ 143,874,000	\$	\$	\$ 143,874,000
Intersegment revenues from discontinued business segments		1,216,000		1,216,000
Interest expense and penalties	107,000	174,000		281,000
Depreciation and amortization	149,000	85,000		234,000
Revenues from discontinued business segments		12,906,000		12,906,000
Segment gain (loss) before allocated overhead	11,522,000	(1,488,000)		10,034,000
Allocated corporate overhead	3,686,000	1,946,000		5,632,000
Segment assets	8,214,000	83,000		8,297,000
Segment gain (loss) after allocated overhead	7,836,000	(3,434,000)		4,402,000

Included in allocated corporate overhead in 2003 was interest revenue of \$27,000, interest expense of \$1,216,000 and depreciation and amortization of \$506,000. In addition, corporate assets were \$927,000.

YEAR ENDED DECEMBER 31, 2002	PSN	Pharmacy	Laboratory	Total
Revenues from external customers	140,064,000			140,064,000
Intersegment revenues from discontinued business segments		1,174,000		1,174,000
Interest expense and penalties	16,000	24,000		40,000
Depreciation and amortization	397,000	95,000	10,000	502,000
Revenue from discontinued business segments		12,875,000	886,000	13,761,000
Segment gain (loss) before allocated overhead	(4,996,000)	(1,767,000)	(1,448,000)	(8,211,000)
Allocated corporate overhead	5,446,000	2,970,000	454,000	8,870,000
Segment assets	5,662,000	3,419,000		9,081,000

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

Segment gain (loss) after allocated overhead (10,442,000) (4,737,000) (1,902,000) (17,081,000)

Included in allocated corporate overhead in 2002 was interest revenue of \$23,000, interest expense of \$2,405,000 and depreciation and amortization of \$549,000. In addition, corporate assets were \$1,078,000.

YEAR ENDED DECEMBER 31,2001	PSN	Pharmacy	Laboratory	Total
Revenues from external customers	128,186,000			128,186,000
Intersegment revenues		296,000		296,000
Interest and penalties		42		42
Depreciation and amortization	355,000	15,000	10,000	380,000
Revenues from discontinued business segments		2,781,000	563,000	3,344,000
Segment gain (loss) before allocated overhead	6,142,000	(744,000)	(559,000)	4,839,000
Allocated corporate overhead	3,911,000	860,000	437,000	5,208,000
Segment assets	12,292,000	2,388,000	1,544,000	16,224,000
Segment gain (loss) after allocated overhead	2,231,000	(1,604,000)	(996,000)	(369,000)

Included in allocated corporate overhead in 2003 was interest revenue of \$12,000, interest expense of \$649,000 and depreciation and amortization of \$491,000. In addition, corporate assets were \$911,000.

Table of Contents**METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****NOTE 14. SUBSEQUENT EVENTS**

In January 2004, \$715,000 of long-term debt was paid in full through the issuance of 1.3 million shares of common stock, as provided for in the terms of the Convertible Notes with the investors. In addition, with payments of \$170,000 in January 2004 and \$450,000 in March 2004, the remaining balance of \$620,000 on a second Note was repaid.

In June 2003, the Company was informed that the U.S. Attorneys Office in Wilmington, Delaware was conducting an investigation of the Company. The Company fully cooperated with the U.S. Attorneys Office and on February 9, 2004 the investigation was terminated.

In February 2004 the Company was successful in negotiating a settlement with the IRS on its outstanding payroll tax liabilities for an amount totaling approximately \$3.3 to \$3.4 million. To date, \$3.2 million of this settlement has been paid with the balance to be paid once the IRS has determined the final settlement amount.

In conjunction with its IRS settlement, in February 2004 the Company issued approximately 5.0 million shares of common stock in connection with a private placement, resulting in proceeds of \$3.0 million that was used to settle the IRS obligations.

In March 2004, two Notes due August 2004 totaling \$300,000 were repaid through the issuance of approximately 611,000 shares of common stock. Additionally, the Company finalized an extension, for payment over twenty-four months, of approximately \$1.2 million in debt due May 2004. 100,000 shares of Company stock were issued in conjunction with the debt.

NOTE 15. VALUATION AND QUALIFYING ACCOUNTS

Activity in the Company's Valuation and Qualifying Accounts consists of the following:

	Year Ended December 31,		
	2003	2002	2001
Allowance for doubtful accounts-continuing operations			
Balance at beginning of period	\$ 4,648,000	\$ 4,734,000	\$ 5,065,000
Charged to costs and expenses	100,000	770,000	1,063,000
Deductions	(2,209,000)	(856,000)	(1,394,000)
	<hr/>	<hr/>	<hr/>
Balance at end of period	\$ 2,539,000	\$ 4,648,000	\$ 4,734,000
	<hr/>	<hr/>	<hr/>
Allowance for doubtful accounts-discontinued operations:			
Balance at beginning of period	\$ 314,756	\$ 13,925	\$
Charged to costs and expenses	786,576	300,831	208,490
Deductions	(1,101,332)		(194,565)

	_____	_____	_____
Balance at end of period	\$	\$ 314,756	\$ 13,925
	_____	_____	_____
Deferred tax asset valuation allowance:			
Balance at beginning of period	\$13,154,000	\$ 6,765,000	\$ 7,221,000
Additions		6,389,000	
Deductions	(1,449,000)		(456,000)
	_____	_____	_____
Balance at end of period	\$11,705,000	\$13,154,000	\$ 6,765,000
	_____	_____	_____

F-31

Table of Contents

_____ Shares

**Metropolitan Health
Networks, Inc.**

PROSPECTUS

_____, 2004

Table of Contents**PART II****INFORMATION NOT REQUIRED IN PROSPECTUS****Item 24. *Indemnification of Directors and Officers***

The Florida Business Corporation Act (the Corporation Act) permits the indemnification of directors, employees, officers and agents of Florida corporations. Our Articles of Incorporation (the articles) and Bylaws provide that we shall indemnify our directors and officers to the fullest extent permitted by the Corporation Act.

The provisions of the Corporation Act that authorize indemnification do not eliminate the duty of care of a director, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Florida law. In addition, each director will continue to be subject to liability for (a) violations of criminal laws, unless the director had reasonable cause to believe his conduct was lawful or had no reasonable cause to believe his conduct was unlawful, (b) deriving an improper personal benefit from a transaction, (c) voting for or assenting to an unlawful distribution and (d) willful misconduct or conscious disregard for our best interests in a proceeding by or in the right of a shareholder. The statute does not affect a director's responsibilities under any other law, such as the Federal securities laws.

The effect of the foregoing is to require us to indemnify our officers and directors for any claim arising against such persons in their official capacities if such person acted in good faith and in a manner that he reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

Item 25. *Other Expenses of Issuance and Distribution*

The estimated expenses payable by us in connection with the distribution of the securities being registered are as follows:

SEC Registration and Filing Fee	\$ 608.31
Legal Fees and Expenses*	5,000.00
Accounting Fees and Expenses*	4,000.00
Financial Printing*	1,000.00
Transfer Agent Fee*	500.00
Blue Sky Fees and Expenses*	
Miscellaneous*	250.00
TOTAL	\$ 11,358.31

* Estimated

None of the foregoing expenses are being paid by the selling security holders.

Item 26. *Recent sales of Unregistered Securities*

In May 2001, we sold 350,000 shares of our common stock to an accredited investor for a total purchase price of \$647,500 or \$1.85 per share. The issuance of these shares was exempt from registration under Section 4(2) of the Securities Act. The investor had access to information concerning our company and had the ability to ask questions regarding our company. The investor represented that he was purchasing the shares for investment purposes. The shares were marked with the appropriate restrictive legends.

On May 4, 2001, we issued warrants to purchase 15,000 shares of our common stock to a financial consultant as consideration for providing financial and other advisory consulting services. The warrants are exercisable at \$1.85 per share. The warrants expire on May 4, 2006. The issuance of these warrants was exempt from registration under Section 4(2) of the Securities Act. The consultant had the opportunity to ask questions regarding our company and had access to relevant information regarding our company. The warrants received by the consulting company contained the appropriate restrictive legends.

From October 26, 2001, through January 22, 2002, we raised \$1,129,548 through the issuance of a series of notes to a non-affiliated third party. The notes were convertible into shares of our common stock at conversion rates ranging from \$.82 per share to \$1.35 per share. All of the notes have been converted into a total of 1,157,778 shares of common stock. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

Table of Contents

On December 12, 2001, we reached an agreement with a non-affiliated third party where we agreed to pay the non-affiliated third party a fee payable in our common stock in the amount of 7% of any capital received by us as a result of an introduction by the non-affiliated third party. We have issued the non-affiliated third party a total of 15,500 shares of our common stock under the agreement. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On December 29, 2001 and February 18, 2002, we received a total of \$800,000 for the issuance of a total of 800,000 shares of our common stock to a non-affiliated third party pursuant to the terms of Common Stock Purchase Agreements. The Common Stock Purchase Agreements provide for (i) piggy-back registration rights in the event the Company files a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities (other than on Form S-4 or Form S-8), and (ii) mandatory registration within 180 days of the date of purchase. In the event the mandatory registration provision is not complied with, the Common Stock Purchase Agreements provide that the investor shall receive additional shares of our common stock for each month until the shares are registered pursuant to the terms of the Agreement. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2002, we reached an agreement with a non-affiliated third party where we agreed to pay the non-affiliated third party a fee payable in our common stock in the amount of 10% of any capital received by us as a result of an introduction by the non-affiliated third party. On February 11, 2002, we issued the non-affiliated third party 30,000 shares of our common stock. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2002, we issued an aggregate of 66,165 shares of our common stock to our directors under our director compensation agreements as compensation for their services rendered during 2001. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On January 2, 2002, we issued 45,894 shares of our common stock to a non-affiliated individual pursuant to a Settlement Agreement and Mutual General Release dated March 19, 2001. The Settlement Agreement provided for the issuance of 100,000 shares of our common stock having a value of no less than \$300,000. The Settlement Agreement further provided that in the event the value of the issued shares of common stock was below \$300,000 on the date of the filing of a registration statement covering those shares, we would then become obligated to issue to the non-affiliated individual additional shares of our common stock to bring the total value of all shares issued to no less than \$300,000. The issuance of 45,894 shares of our common stock on January 2, 2002, satisfied the foregoing condition of the Settlement Agreement. The Settlement Agreement provided piggy-back registration rights with respect to the additional shares issued on January 2, 2002. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On January 9, 2002, we issued 150 shares of our common stock to an individual at \$1.00 per share. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On February 7, 2002, we issued 113,073 shares of our common stock to an individual in consideration for services rendered pursuant to a Services Agreement dated December 31, 2001. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On February 11, 2002, we issued 1,241,778 shares of our common stock to an entity upon the conversion of principal and interest under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On February 12, 2002, we issued 10,500 shares of our common stock to an entity as a commission with respect to a private placement of equity securities. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On February 12, 2002, we issued 67 shares of our common stock to an individual upon his exercise of common stock purchase options. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On February 12, 2002, we sold 300,000 shares of our common stock to a non-affiliated third party at \$1.00 per share. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On February 21, 2002, we issued 35,000 shares of our common stock to a non-affiliated third party in connection with a financing through which we raised \$500,000 through the issuance of a secured promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

Table of Contents

On February 22, 2002, we issued 50,000 shares of our common stock to an individual at \$1.00 per share. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On March 1, 2002, we issued 38,475 shares of our common stock to an entity pursuant to a draw down on an equity line agreement. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

We issued 179,720 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

We issued 336,000 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

On July 31, 2002, in consideration of the cancellation of a warrant to purchase 65,000 shares of our common stock, the amendment and restatement of a previously issued convertible note, and the receipt of \$344,225, we issued to a non-affiliated third party warrants to purchase 300,000 shares of our common stock exercisable at \$0.65 per share until July 31, 2007, and a convertible note in the principal amount of \$344,225 with interest at the rate of 6.0% per annum. The warrants and convertible note were issued under the exemption provided by Section 4(2) of the Securities Act.

On September 25, 2002, in consideration of services rendered and to be rendered under a Financial Advisory and Consulting Agreement, we issued a non-affiliated third party a warrant to purchase 200,000 shares of our common stock at \$0.40 per share, exercisable for a period of three years. The warrant was issued under the exemption provided by Section 4(2) of the Securities Act.

In December 2002, in consideration of the amendment of the repayment schedules of certain notes previously issued to a non-affiliated third party, we issued the non-affiliated third party a warrant to purchase 40,625 shares of our common stock at \$0.32 per share, exercisable for five years. The warrant was issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2003, we issued 102,433 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2003, we issued 100,000 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2003, we issued 75,000 shares of our common stock to a non-affiliated third party in settlement of a claim. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In February 2003, we issued 100,000 shares of our common stock to an individual in conjunction with a employment contract amendment. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In February 2003, we issued 40,103 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In February 2003, we issued an aggregate of 128,872 shares of our common stock to an entity upon the conversion of principal and interest under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

In February 2003, we issued 900,000 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In March 2003, we issued an aggregate of 58,194 shares of our common stock to our directors under our director compensation agreements as compensation for their services rendered during 2002. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In March 2003, we issued an aggregate of 369,987 shares of our common stock to an entity upon the conversion of principal and interest under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

II-3

Table of Contents

In April 2003, we issued an aggregate of 1,515,272 shares of our common stock to a pair of entities upon the conversion of interest under convertible promissory notes. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In April 2003, we issued 150,000 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In May 2003, we issued an aggregate of 62,654 shares of our common stock to our directors under our director compensation agreements as compensation for their services rendered during 2003. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In July 2003, we issued an aggregate of 162,952 shares of our common stock to our directors under our director compensation agreements as compensation for their services rendered during 2003. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In August 2003, we issued 251,463 shares of our common stock to an entity upon the conversion of principal and interest under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In September 2003, we issued 279,671 shares of our common stock to an entity upon the conversion of principal and interest under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In October 2003, we issued an aggregate of 45,960 shares of our common stock to our directors under our director compensation agreements as compensation for their services rendered during 2003. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In October 2003, we issued an aggregate of 1,284,639 shares of our common stock to a pair of entities upon the conversion of principal and interest under convertible promissory notes. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In November 2003, we issued an aggregate of 1,357,582 shares of our common stock to a pair of entities upon the conversion of principal and interest under convertible promissory notes. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In November 2003, we issued 238,095 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In December 2003, we issued 100,000 shares of our common stock to a director upon exercise of options. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2004, we issued an aggregate of 1,258,372 shares of our common stock to an entity upon the conversion of principal and interest under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In January 2004, we issued an aggregate of 4,400 shares of our common stock to employees upon exercise of options. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In February 2004, we issued an aggregate of 104,580 shares of our common stock to our directors under our director compensation agreements as compensation for their services rendered during 2003. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In February 2004, we issued an aggregate of 12,500 shares of our common stock to employees upon exercise of options. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

Table of Contents

In February 2004, we also sold an aggregate of 5,004,999 shares of our common stock to 24 accredited and 1 non-accredited investors. The shares were sold for \$0.60 per share. We received \$3,003,000 in proceeds from the sale of these shares. The Company paid \$50,000 in commissions relating to the sales. The shares of common stock were issued under the exemption from registration provided by Section 4(2) of the Securities Act. The investors received current information about our company and had the opportunity to ask questions about our company. The investors purchased the shares for investment purposes and the shares they received were marked with the appropriate restrictive legend.

In March 2004, we issued an aggregate of 390,698 shares of our common stock to an individual upon the conversion of principal under a convertible promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In March 2004, we issued an aggregate of 220,000 shares of our common stock to an individual in repayment of a \$132,000 promissory note. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In March 2004, we issued an aggregate of 69,100 shares of our common stock to current and former employees upon exercise of options. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In March 2004, we issued 100,000 shares of our common stock to a non-affiliated third party in consideration of services rendered. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

In April 2004, we issued an aggregate of 21,300 shares of our common stock to current and former employees upon exercise of options. The shares were issued under the exemption provided by Section 4(2) of the Securities Act.

Each of the security holders (a) had access to business and financial information concerning the Company, (b) represented that it was acquiring the securities for investment purposes only and not with a view towards distribution or resale except in compliance with applicable securities laws and (c) had such knowledge and experience in business and financial matters that he, she or its was able to evaluate the risks and merits of an investment in the Company. Therefore, each investor was also sophisticated within the meaning of Federal securities laws. In addition, the certificates evidencing the securities that were issued contained a legend restricting their transferability absent registration under the Securities Act or the availability of an applicable exemption therefrom.

Item 27. Exhibits and Financial Statement Schedules

Exhibit No.	Description of Document
3.1	- Articles of Incorporation.(1)
3.2	- Articles of Amendment to the Articles of Incorporation.(1)
3.3	- By-laws.(1)
3.4	- Articles of Amendment to the Articles of Incorporation designating the Series A Preferred Stock.(4)
3.5	-

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form S-1

Articles of Amendment to the Articles of Incorporation designating the Series B Preferred Stock.(4)

- 3.6 - Articles of Amendment to the Articles of Incorporation.(4)
- 4.1 - Specimen Common Stock Certificate.(1)
- 5.1 - Opinion of Adorno & Yoss, P.A.(3)
- 10.1 - Form of Subscription Agreement (3)
- 10.2 - Amendment #1 to Note between Registrant and Global Capital Funding Group, L.P. dated March 19, 2004 (3)
- 10.3 - Subscription Agreement between Registrant and Michael Rosenbaum dated March 8, 2004 (3)
- 10.4 - 6% Convertible Debenture between Registrant and Michael Rosenbaum dated October 1, 2002. (3)
- 21 - Subsidiaries of the Company (2)
- 23.1 - Consent of Kaufman, Rossin and Company.(3)
- 23.2 - Consent of Adorno & Yoss, P.A. (contained in Exhibit 5.1)

Table of Contents

- (1) Incorporated by reference to the exhibit of the same number filed with the Company's Registration Statement on Form SB-2 (No. 333-5884-A)
- (2) Incorporated by reference to the exhibit filed with the Company's Registration Statement on Form SB-2 (No. 333-84220) on March 13, 2002.
- (3) Filed herewith.
- (4) Filed previously.

Item 28. Undertakings

The undersigned Registrant undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-3 or Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

Table of Contents**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on this Form S-1 and authorized this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in West Palm Beach, Florida on May 26, 2004.

METROPOLITAN HEALTH NETWORKS,
INC

By: /s/ Michael M. Earley

Michael M. Earley, President and Chief
Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Form S-1 registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signatures	Title	Date
<u>/s/ Michael M. Earley</u> Michael M. Earley	Director, President and Chief Executive Officer	May 26, 2004
<u>/s/ Debra A. Finnel</u> Debra A. Finnel	Director, Vice President and Chief Operating Officer	May 26, 2004
<u>/s/ David S. Gartner</u> David S. Gartner	Chief Financial Officer and Principal Accounting Officer	May 26, 2004
<u>/s/ Roberto Palenzuela</u> Roberto Palenzuela	Secretary and General Counsel	May 26, 2004
<u>/s/ Martin Harrison</u> Martin Harrison	Director	May 26, 2004
<u>/s/ Dr. Salomon E. Melgen</u> Salomon E. Melgen	Director	May 26, 2004
<u>/s/ Karl Sachs</u>	Director	May 26, 2004

Karl Sachs

II-7